US20060040363A1 - Human antibodies derived from immunized xenomice - Google Patents
Human antibodies derived from immunized xenomice Download PDFInfo
- Publication number
- US20060040363A1 US20060040363A1 US10/656,623 US65662303A US2006040363A1 US 20060040363 A1 US20060040363 A1 US 20060040363A1 US 65662303 A US65662303 A US 65662303A US 2006040363 A1 US2006040363 A1 US 2006040363A1
- Authority
- US
- United States
- Prior art keywords
- human
- antibody
- leukocyte marker
- immunoglobulin
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 claims abstract description 88
- 108091007433 antigens Proteins 0.000 claims abstract description 88
- 102000036639 antigens Human genes 0.000 claims abstract description 88
- 241001465754 Metazoa Species 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 88
- 210000000265 leukocyte Anatomy 0.000 claims description 66
- 108060003951 Immunoglobulin Proteins 0.000 claims description 65
- 102000018358 immunoglobulin Human genes 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102100032937 CD40 ligand Human genes 0.000 claims description 28
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 claims description 28
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 28
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 26
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 25
- 229940072221 immunoglobulins Drugs 0.000 claims description 22
- 108010092694 L-Selectin Proteins 0.000 claims description 21
- 102000016551 L-selectin Human genes 0.000 claims description 21
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 21
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 101150013553 CD40 gene Proteins 0.000 claims description 17
- -1 IL-14 Proteins 0.000 claims description 17
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 210000004408 hybridoma Anatomy 0.000 claims description 17
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 16
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 16
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 14
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 11
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 11
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 11
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 11
- 102100027207 CD27 antigen Human genes 0.000 claims description 11
- 102100032912 CD44 antigen Human genes 0.000 claims description 11
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 11
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 11
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 11
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 11
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 11
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 11
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 11
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 11
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 11
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 11
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 11
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 11
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 11
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 11
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 11
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 11
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 11
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 11
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 11
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 11
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 11
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 11
- 108010029485 Protein Isoforms Proteins 0.000 claims description 11
- 102000001708 Protein Isoforms Human genes 0.000 claims description 11
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 11
- 229940112129 campath Drugs 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 10
- 108090001007 Interleukin-8 Proteins 0.000 claims description 10
- 102000004890 Interleukin-8 Human genes 0.000 claims description 10
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 9
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 9
- 102000052611 human IL6 Human genes 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 7
- 102000057041 human TNF Human genes 0.000 claims description 7
- 229940118376 tetanus toxin Drugs 0.000 claims description 7
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims description 6
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims description 6
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims description 6
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims description 6
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102000004264 Osteopontin Human genes 0.000 claims description 6
- 108010081689 Osteopontin Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 102000000704 Interleukin-7 Human genes 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 3
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims description 3
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims description 3
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims description 3
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 claims description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 3
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 3
- 108010084313 CD58 Antigens Proteins 0.000 claims description 3
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 3
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims description 3
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 3
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 3
- 108010078015 Complement C3b Proteins 0.000 claims description 3
- 108010078546 Complement C5a Proteins 0.000 claims description 3
- 108010024212 E-Selectin Proteins 0.000 claims description 3
- 102100023471 E-selectin Human genes 0.000 claims description 3
- 102100038083 Endosialin Human genes 0.000 claims description 3
- 101710144543 Endosialin Proteins 0.000 claims description 3
- 108050009340 Endothelin Proteins 0.000 claims description 3
- 102000002045 Endothelin Human genes 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000057955 Eosinophil Cationic Human genes 0.000 claims description 3
- 102000056703 Eosinophil Major Basic Human genes 0.000 claims description 3
- 108700016651 Eosinophil Major Basic Proteins 0.000 claims description 3
- 101710191360 Eosinophil cationic protein Proteins 0.000 claims description 3
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 3
- 101710102442 Erythropoietin receptor Proteins 0.000 claims description 3
- 108091008794 FGF receptors Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 3
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 3
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 claims description 3
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 3
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 3
- 102100032817 Integrin alpha-5 Human genes 0.000 claims description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 3
- 108010041341 Integrin alpha1 Proteins 0.000 claims description 3
- 108010055795 Integrin alpha1beta1 Proteins 0.000 claims description 3
- 108010017642 Integrin alpha2beta1 Proteins 0.000 claims description 3
- 108010072255 Integrin alpha3beta1 Proteins 0.000 claims description 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 3
- 108010041014 Integrin alpha5 Proteins 0.000 claims description 3
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims description 3
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 3
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 3
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 108010002386 Interleukin-3 Proteins 0.000 claims description 3
- 102000000646 Interleukin-3 Human genes 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 108010002616 Interleukin-5 Proteins 0.000 claims description 3
- 102000000743 Interleukin-5 Human genes 0.000 claims description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 101150113776 LMP1 gene Proteins 0.000 claims description 3
- 102000043129 MHC class I family Human genes 0.000 claims description 3
- 108091054437 MHC class I family Proteins 0.000 claims description 3
- 102000043131 MHC class II family Human genes 0.000 claims description 3
- 108091054438 MHC class II family Proteins 0.000 claims description 3
- 101710091439 Major capsid protein 1 Proteins 0.000 claims description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 3
- 102000005741 Metalloproteases Human genes 0.000 claims description 3
- 108010006035 Metalloproteases Proteins 0.000 claims description 3
- 102000006386 Myelin Proteins Human genes 0.000 claims description 3
- 108010083674 Myelin Proteins Proteins 0.000 claims description 3
- 108010035766 P-Selectin Proteins 0.000 claims description 3
- 102100023472 P-selectin Human genes 0.000 claims description 3
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims description 3
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims description 3
- 102100036154 Platelet basic protein Human genes 0.000 claims description 3
- 102100030304 Platelet factor 4 Human genes 0.000 claims description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 102000003800 Selectins Human genes 0.000 claims description 3
- 108090000184 Selectins Proteins 0.000 claims description 3
- 102100029337 Thyrotropin receptor Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 239000003659 bee venom Substances 0.000 claims description 3
- 229960000182 blood factors Drugs 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 3
- 229940044627 gamma-interferon Drugs 0.000 claims description 3
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 claims description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000003966 growth inhibitor Substances 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 108010093036 interleukin receptors Proteins 0.000 claims description 3
- 102000002467 interleukin receptors Human genes 0.000 claims description 3
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 3
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 3
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 claims description 3
- 108040006873 interleukin-11 receptor activity proteins Proteins 0.000 claims description 3
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 claims description 3
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims description 3
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 3
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 3
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 3
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 3
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 claims description 3
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 3
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 claims description 3
- 108010038415 interleukin-8 receptors Proteins 0.000 claims description 3
- 102000010681 interleukin-8 receptors Human genes 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 210000005012 myelin Anatomy 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims description 3
- 239000003998 snake venom Substances 0.000 claims description 3
- 210000004989 spleen cell Anatomy 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims description 3
- 102000004266 Collagen Type IV Human genes 0.000 claims description 2
- 108010042086 Collagen Type IV Proteins 0.000 claims description 2
- 102000001617 Interferon Receptors Human genes 0.000 claims description 2
- 108010054267 Interferon Receptors Proteins 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 64
- 102100021696 Syncytin-1 Human genes 0.000 claims 12
- 102000053602 DNA Human genes 0.000 claims 11
- 101150043916 Cd52 gene Proteins 0.000 claims 8
- 230000003247 decreasing effect Effects 0.000 claims 5
- 108020004511 Recombinant DNA Proteins 0.000 claims 3
- 108700012434 CCL3 Proteins 0.000 claims 2
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 2
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 claims 2
- 108010073816 IgE Receptors Proteins 0.000 claims 2
- 102000009438 IgE Receptors Human genes 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000003815 Interleukin-11 Human genes 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 abstract description 12
- 230000004044 response Effects 0.000 abstract description 6
- 230000000890 antigenic effect Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 33
- 238000012452 Xenomouse strains Methods 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 24
- 101100102451 Human herpesvirus 8 type P (isolate GK18) K4.1 gene Proteins 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 241001529936 Murinae Species 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 238000002649 immunization Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000012286 ELISA Assay Methods 0.000 description 6
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000002596 immunotoxin Substances 0.000 description 4
- 229940051026 immunotoxin Drugs 0.000 description 4
- 230000002637 immunotoxin Effects 0.000 description 4
- 231100000608 immunotoxin Toxicity 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000000954 titration curve Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000005257 nucleotidylation Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- ROICYBLUWUMJFF-RDTXWAMCSA-N (6aR,9R)-N,7-dimethyl-N-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound CN(C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34)C(C)C ROICYBLUWUMJFF-RDTXWAMCSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102100039147 Dimethyladenosine transferase 2, mitochondrial Human genes 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889470 Homo sapiens Dimethyladenosine transferase 2, mitochondrial Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102100028644 Tenascin-R Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- GKBMIFPNPOSTHB-BJBKLNMKSA-N recombinant soluble cd4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 108010020387 tenascin R Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Definitions
- the invention relates to the field of immunology, and in particular to the production of antibodies. More specifically, it concerns producing such antibodies by a process which includes the step of immunizing a transgenic animal with an antigen to which antibodies are desired.
- the transgenic animal has been modified so as to produce human, as opposed to endogenous antibodies.
- Antibodies with various immunospecificities are desirable for therapeutic and diagnostic use.
- Those antibodies intended for human therapeutic and in vivo diagnostic use have been problematic because prior art sources for such antibodies resulted in immunoglobulins bearing the characteristic structures of antibodies produced by nonhuman hosts. Such antibodies tend to be immunogenic when used in humans.
- the invention is directed to methods to produce human antibodies by a process wherein at least one step of the process includes immunizing a transgenic nonhuman animal with the desired antigen.
- the modified animal fails to produce endogenous antibodies, but instead produces B-cells which secrete immunoglobulins with fully human variable regions.
- the antibodies produced include fully human antibodies and can be obtained from the animal directly, or from immortalized B-cells derived from the animal. Alternatively, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly or modified to obtain analogs of antibodies such as, for example, single chain F V molecules.
- the invention is directed to a method to produce an immunoglobulin with a fully human variable region to a specific antigen or to produce an analog of said immunoglobulin by a process which comprises immunizing a nonhuman animal with the antigen under conditions that stimulate an immune response.
- the nonhuman animal is characterized by being substantially incapable of producing endogenous heavy or light immunoglobulin chain, but capable of producing immunoglobulins either with both human variable regions and constant regions or with fully human variable regions or both.
- the animal produces B cells which secrete immunoglobulins, with at least variable regions that are fully human, specific for the antigen.
- the human immunoglobulin of desired specificity can be directly recovered from the animal, for example, from the serum, or primary B cells can be obtained from the animal and immortalized.
- the immortalized B cells can be used directly as the source of human antibodies or, alternatively, the genes encoding the antibodies can be prepared from the immortalized B cells or from primary B cells of the blood or lymphoid tissue (spleen, tonsils, lymph nodes, bone marrow) of the immunized animal and expressed in recombinant hosts, with or without modification, to produce the immunoglobulin or its analogs.
- the genes encoding the repertoire of immunoglobulins produced by the immunized animal can be used to generate a library of immunoglobulins to permit screening for those variable regions which provide the desired affinity. Clones from the library which have the desired characteristics can then be used as a source of nucleotide sequences encoding the desired variable regions for further manipulation to generate antibodies or analogs with these characteristics using standard recombinant techniques.
- the invention relates to an immortalized nonhuman B cell line derived from the above described animal.
- the invention is directed to a recombinant host cell which is modified to contain the gene encoding either the human immunoglobulin with the desired specificity, or an analog thereof which exhibits the same specificity.
- the invention is directed to antibodies or antibody analogs prepared by the above described methods and to recombinant materials for their production.
- the invention is directed to antibodies with fully human variable regions, including fully human antibodies which are immunospecific with respect to particular antigens set forth herein and to analogs which are similarly immunospecific, as well as to the recombinant materials useful in the production of these antibodies.
- FIG. 1 shows the serum titers of anti-IL-6 antibodies from a xenomouse immunized with human IL-6 and which antibodies contain human kappa light chains and/or human ⁇ heavy chains.
- FIG. 2 shows the serum titers of anti-IL-8 antibodies from a xenomouse immunized with human IL-8 and which antibodies contain human kappa light chains and/or human ⁇ heavy chains.
- FIG. 3 shows the serum titers of anti-TNF ⁇ antibodies from a xenomouse immunized with human TNF- ⁇ and which antibodies contain human kappa light chains and/or human ⁇ heavy chains.
- FIG. 4 shows the serum titers of anti-CD4 antibodies from a xenomouse immunized with human CD4 and which antibodies contain human kappa light chains and/or human ⁇ heavy chains.
- FIG. 5 shows the serum titers of a xenomouse immunized with 300.19 cells expressing L-selectin at their surface. In the ELISA assay used, these antibodies are detectable only if they carry human ⁇ constant region heavy chains.
- FIG. 6 shows the serum titers of a xenomouse immunized with 300.19 cells expressing L-selectin at their surface. In the ELISA assay used, these antibodies are detectable only if they carry human kappa light chains.
- FIG. 7 shows the serum titers of a xenomouse immunized with 300.19 cells expressing L-selectin.
- these antibodies are detectable if they carry human kappa light chain and/or murine y constant regions.
- FIG. 8 shows a FACS analysis of human neutrophils coupled to sera from a xenomouse (A195-2) immunized with human L-selectin and labeled with an antibody immunoreactive with murine heavy chain ⁇ constant region.
- FIG. 9 shows a FACS analysis of human neutrophils incubated with serum from a xenomouse (A195-2) immunized with human L-selectin and labeled with an antibody immunoreactive with human light chain kappa region.
- FIG. 10 is a diagram of a plasmid used to transfect mammalian cells to effect the production of the human protein gp39.
- FIG. 11 represents the serum titration curve of mice immunized with CHO cells expressing human gp39.
- the antibodies detected in this ELISA must be immunoreactive with gp39 and contain human heavy chain ⁇ constant regions or human kappa light chains.
- FIG. 12 shows the results of a FACS analysis of antibodies from a xenomouse (labeled A247-4) immunized with human gp39 reacted with activated human T cells.
- FIG. 12A shows the separation of human activated T cells into CD4+ and CD4 ⁇ populations.
- Panel B shows the results of a FACS analysis of the activated CD4+ T cells with antibodies from the xenomouse immunized with gp39 which contain murine heavy chain ⁇ constant regions;
- panel C shows the corresponding results with respect to CD4 ⁇ populations.
- FIG. 13 is a titration curve with respect to monoclonal antibodies secreted by the hybridoma clone D5.1.
- This clone is obtained from a xenomouse immunized with tetanus toxin C (TTC) and contains human kappa light chain and human ⁇ constant region in the heavy chain.
- TTC tetanus toxin C
- FIG. 14 is a titration curve with respect to the hybridoma supernatant from clone K4.1.
- This hybridoma clone is obtained from a xenomouse immunized with TTC and contains human kappa light chain and heavy chain having the murine ⁇ constant region.
- FIG. 15 shows binding curves for various concentrations of the K4.1 monoclonal antibody in a determination of the affinity of the monoclonal with its antigen in a BIAcore instrument.
- FIG. 16 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by K4.1.
- FIG. 17 shows the complete nucleotide sequence of the light chain from the antibody secreted by K4.1.
- FIG. 18 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by D5.1.
- FIG. 19 shows the complete nucleotide sequence of the light chain from the antibody secreted by D5.1.
- the methods of the invention include administering an antigen for which human forms of immunospecific reagents are desired to a transgenic nonhuman animal which has been modified genetically so as to be capable of producing human, but not endogenous, antibodies.
- the animal has been modified to disable the endogenous heavy and/or light chain loci in its genome, so that these endogenous loci are incapable of the rearrangement required to generate genes encoding immunoglobulins in response to an antigen.
- the animal will have been provided, stably, in its genome, at least one human heavy chain locus and at least one human light chain locus so that in response to an administered antigen, the human loci can rearrange to provide genes encoding human immunoglobulins immunospecific for the antigen.
- the first step is administration of the antigen.
- Techniques for such administration are conventional and involve suitable immunization protocols and formulations which will depend on the nature of the antigen per se. It may be necessary to provide the antigen with a carrier to enhance its immunogenicity and/or to include formulations which contain adjuvants and/or to administer multiple injections, and the like. Such techniques are standard and optimization of them will depend on the characteristics of the particular antigen for which immunospecific reagents are desired.
- immunospecific reagents includes immunoglobulins and their analogs.
- analogs has a specific meaning in this context. It refers to moieties that contain the fully human portions of the immunoglobulin which account for its immunospecificity. In particular, variable regions including the complementarity determining regions (CDRs) are required, along with sufficient portions of the framework regions (FRs) to result in the appropriate three dimensional conformation.
- Typical immunospecific analogs of antibodies include F (ab′) 2 , F ab′ , and F ab regions. Modified forms of the variable regions to obtain, for example, single chain F V analogs with the appropriate immunospecificity are known. A review of such F V construction is found, for example, in Tibtech (1991) 9:________. The construction of antibody analogs with multiple immunospecificities is also possible by coupling the human variable regions derived from antibodies with varying specificities.
- variable regions with fully human characteristics can also be coupled to a variety of additional substances which can provide toxicity, biological functionality, alternative binding specificities and the like.
- the moieties including the fully human variable regions produced by the methods of the invention include single-chain fusion proteins, molecules coupled by covalent methods other than those involving peptide linkages, and aggregated molecules. Examples of analogs which include variable regions coupled to additional molecules covalently or noncovalently include those in the following nonlimiting illustrative list. Traunecker, A. et al. Int J Cancer Supp (1992) Supp 7:51-52 describe the bispecific reagent janusin in which the F V region directed to CD3 is coupled to soluble CD4 or to other ligands such as OVCA and IL-7.
- the fully human variable regions produced by the method of the invention can be constructed into F V molecules and coupled to alternative ligands such as those illustrated in the cited article.
- Higgins, P. J. et al. J Infect Disease (1992) 166:198-202 describe a heteroconjugate antibody composed of OKT3 cross-linked to an antibody directed to a specific sequence in the V3 region or GP120.
- Such heteroconjugate antibodies can also be constructed using at least the human variable regions contained in the immunoglobulins produced by the invention methods. Additional examples of bispecific antibodies include those described by Fanger, M. W. et al. Cancer Treat Res (1993) 68:181-194 and by Fanger, M. W. et al.
- Conjugates that are immunotoxins including conventional antibodies have been widely described in the art.
- the toxins may be coupled to the antibodies by conventional coupling techniques or immunotoxins containing protein toxin portions can be produced as fusion proteins.
- the analogs of the present invention can be used in a corresponding way to obtain such immunotoxins.
- Illustrative of such immunotoxins are those described by Byrs, B. S. et al. Seminars Cell Biol (1991) 2:59-70 and by Fanger, M. W. et al. Immunol Today (1991) 12:51-54.
- the genes encoding the immunoglobulins produced by the transgenic animals of the invention can be retrieved and the nucleotide sequences encoding the fully human variable region can be manipulated according to known techniques to provide a variety of analogs such as those described above.
- the immunoglobulins themselves containing the human variable regions can be modified using standard coupling techniques to provide conjugates retaining immunospecificity and fully human characteristics in the immunospecific region.
- immunoglobulin “analogs” refers to moieties which contain those portions of the antibodies of the invention which retain their human characteristics and their immunospecificity. These will retain sufficient human variable region to provide the desired specificity.
- all of the methods of the invention include administering the appropriate antigen to the transgenic animal.
- the recovery or production of the antibodies themselves can be achieved in various ways.
- the polyclonal antibodies produced by the animal and secreted into the bloodstream can be recovered using known techniques. Purified forms of these antibodies can, of course, be readily prepared by standard purification techniques, preferably including affinity chromatography with respect to the particular antigen, or even with respect to the particular epitope of the antigen for which specificity is desired. In any case, in order to monitor the success of immunization, the antibody levels with respect to the antigen in serum will be monitored using standard techniques such as ELISA, RIA and the like.
- a portion of the polyclonal antiserum obtained may include an endogenous heavy chain constant region derived from the host, even though the variable regions are fully human.
- use of the polyclonal antiserum directly would be inappropriate.
- the presence of these chimeras which is believed to result from in vivo isotype switching as described by Gerstein et al. Cell (1990) 63:537, is not problematic, in view of conventional purification and modification methods and in view of the availability of alternative methods to recover fully human antibodies, if desired, described in the following paragraphs.
- the polyclonal antiserum could be subjected to suitable separation techniques to provide compositions containing only fully human immunoglobulins. Portions of the serum which display characteristics of the host species can be removed, for example, using affinity reagents with the appropriate anti species immunoglobulins or immunospecific portions thereof. Furthermore, for applications where only the variable regions of the antibodies are required, treating the polyclonal antiserum with suitable reagents so as to generate F ab , F ab′ , or F (ab′) 2 portions results in compositions containing fully human characteristics. Such fragments are sufficient for use, for example, in immunodiagnostic procedures involving coupling the immunospecific portions of immunoglobulins to detecting reagents such as radioisotopes. Thus, for some applications, the polyclonal antiserum can be treated to provide compositions with the desired characteristics including compositions consisting essentially of fully human antibodies and compositions including immunoglobulin analogs wherein the immunospecific portion is fully human.
- immunoglobulins and analogs with desired characteristics can be generated from immortalized B cells derived from the transgenic animals used in the method of the invention or from the rearranged genes provided by these animals in response to immunization. It will be apparent that hybridomas derived from the B cells of the immunized animal can be screened so as to choose only those secreting fully human antibodies and that the genetic material can be recovered from the hybridomas or from lymphocytes in spleen, blood, or lymph nodes of the immunized animal and manipulated using conventional techniques to replace any endogenous constant region with a human one or to produce a desired analog.
- the B cells can be obtained, typically from the spleen, but also, if desired, from the peripheral blood lymphocytes or lymph nodes and immortalized using any of a variety of techniques, most commonly using the fusion methods described by Kohler and Milstein.
- the resulting hybridomas (or otherwise immortalized B cells) can then be cultured as single colonies and screened for secretion of antibodies of the desired specificity.
- the screen can also include a determination of the fully human character of the antibody. For example, as described in the examples below, a sandwich ELISA wherein the monoclonal in the hybridoma supernatant is bound both to antigen and to an antihuman constant region can be employed.
- hybridomas that secrete antibodies which are immunoreactive with antispecies antibodies directed to the species of the immunized animal can be discarded.
- the desired antibodies can be recovered, again using conventional techniques. They can be prepared in quantity by culturing the immortalized B cells using conventional methods, either in vitro, or in vivo to produce ascites fluid. Purification of the resulting monoclonal antibody preparations is less burdensome than in the case of serum since each immortalized colony will secrete only a single type of antibody. In any event, standard purification techniques to isolate the antibody from other proteins in the culture medium can be employed.
- the immortalized cells can be used as a source of rearranged heavy chain and light chain loci for subsequent expression and/or genetic manipulation. Isolation of genes from such antibody-producing cells is straightforward since high levels of the appropriate mRNAs are available for production of a cDNA library.
- the recovered rearranged loci can be manipulated as desired. For example, the constant region can be exchanged for that of a different isotype or that of a human antibody, as described above, or eliminated altogether.
- the variable regions can be linked to encode single chain F V regions. Multiple F V regions can be linked to confer binding ability to more than one target or chimeric heavy and light chain combinations can be employed.
- the coding sequences including those that encode, at a minimum, the variable regions of the human heavy and light chain can be inserted into expression systems contained on vectors which can be transfected into standard recombinant host cells.
- host cells As described below, a variety of such host cells may be used; for efficient processing, however, mammalian cells are preferred. Typical mammalian cell lines useful for this purpose include CHO cells, 293 cells, or NSO-GS cells.
- the production of the antibody or analog is then undertaken by culturing the modified recombinant host under culture conditions appropriate for the growth of the host cells and the expression of the coding sequences.
- the antibodies are then recovered from the culture.
- the expression systems are preferably designed to include signal peptides so that the resulting antibodies are secreted into the medium; however, intracellular production is also possible.
- Phage display libraries may also be constructed using previously manipulated nucleotide sequences and screened in similar fashion. In general, the cDNAs encoding heavy and light chain are independently supplied or are linked to form F V analogs for production in the phage library.
- the phage library is thus screened for the antibodies with highest affinity for the antigen and the genetic material recovered from the appropriate clone. Further rounds of screening can increase the affinity of the original antibody isolated.
- the manipulations described above for recombinant production of the antibody or modification to form a desired analog can then be employed.
- the modified or unmodified rearranged loci are manipulated using standard recombinant techniques by constructing expression systems operable in a desired host cell, such as, typically, a Chinese hamster ovary cell, and the desired immunoglobulin or analog is produced using standard recombinant expression techniques, and recovered and purified using conventional methods.
- a desired host cell such as, typically, a Chinese hamster ovary cell
- the desired immunoglobulin or analog is produced using standard recombinant expression techniques, and recovered and purified using conventional methods.
- compositions of the invention will have utilities similar to those ascribable to nonhuman antibodies directed against the same antigen. Such utilities include, for example, use as a affinity ligands for purification, as reagents in immunoassays, as components of immunoconjugates, and as therapeutic agents for appropriate indications.
- antibodies or their analogs with fully human characteristics.
- These reagents avoid the undesired immune responses engendered by antibodies or analogs which have characteristics marking them as originating from non-human species.
- Other attempts to “humanize” antibodies do not result in reagents with fully human characteristics.
- chimeric antibodies with murine variable regions and human constant regions are easily prepared, but, of course, retain murine characteristics in the variable regions.
- Even the much more difficult procedure of “humanizing” the variable regions by manipulating the genes encoding the amino acid sequences that form the framework regions does not provide the desired result since the CDRs, typically of nonhuman origin, cannot be manipulated without destroying immunospecificity.
- the methods of the present invention provide, for the first time, immunoglobulins that are fully human or analogs which contain immunospecific regions with fully human characteristics.
- immunoglobulins and analogs are those immunospecific with respect to human IL-6, human IL-8, human TNF ⁇ , human CD4, human L-selectin, and human gp39.
- Human antibodies against IL-8 are particularly useful in preventing tumor metastasis and inflammatory states such as asthma.
- Antibodies and analogs immunoreactive with human TNF ⁇ and human IL-6 are useful in treating cachexia and septic shock as well as autoimmune disease.
- Antibodies and analogs immunoreactive with gp39 or with L-selectin are also effective in treating or preventing autoimmune disease.
- anti-gp39 is helpful in treating graft versus host disease, in preventing organ transplant rejection, and in treating glomerulonephritis.
- Antibodies and analogs against L-selectin are useful in treating ischemia associated with reperfusion injury.
- Typical autoimmune diseases which can be treated using the above-mentioned antibodies and analogs include systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Sjogren's, scleroderma, mixed connective tissue disease, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, myasthenia gravis and pemphigus.
- mice designated “xenomice”
- xenomice mice, designated “xenomice”
- the sera of the immunized xenomice (or the supernatants from immortalized B cells) were titrated for antigen specific human antibodies in each case using a standard ELISA format. In this format, the antigen used for immunization was immobilized onto wells of microtiter plates. The plates were washed and blocked and the sera (or supernatants) were added as serial dilutions for 1-2 hours of incubation.
- bound antibody having human characteristics was detected by adding the appropriate antispecies Ig (typically antihuman kappa or antihuman ⁇ ) conjugated to horseradish peroxidase (HRP) for one hour.
- HRP horseradish peroxidase
- the bound antibodies were tested for murine characteristics using antimurine antibodies, typically antimurine ⁇ .
- OPD chromogenic reagent o-phenylene diamine
- the antigen was coated using plate coating buffer (0.1 M carbonate buffer, pH 9.6); the assay blocking buffer used was 0.5% BSA, 0.1% Tween 20 and 0.01% Thimerosal in PBS; the substrate buffer used in color development was citric acid 7.14 g/l: dibasic sodium phosphate 17.96 g/l; the developing solution (made immediately before use) was 10 ml substrate buffer, 10 mg OPD, plus 5 ml hydrogen peroxide; the stop solution (used to stop color development) was 2 M sulfuric acid. The wash solution was 0.05% Tween 20 in PBS.
- mice Three to 5 xenomice aged 8-20 weeks were age-matched and immunized intraperitoneally with 50 ⁇ g human IL-6 emulsified in complete Freund's adjuvant for primary immunization and in incomplete Freund's adjuvant for subsequent injections. The mice received 6 injections 2-3 weeks apart. Serum titers were determined after the second dose and following each dose thereafter. Bleeds were performed 6-7 days after injections from the retrobulbar plexus. The blood was allowed to clot at room temperature for about 2 hours and then incubated at 4° C. for at least 2 hours before separating and collecting the sera.
- ELISAs were conducted as described above by applying 100 ⁇ l per well of recombinant human IL-6 at 2 mg/ml in coating buffer. Plates were then incubated at 4° C. overnight or at 37° C. for 2 hours and then washed three times in washing buffer. Addition of 100 ⁇ l/well blocking buffer was followed by incubation at room temperature for 2 hours, and an additional 3 washes.
- Immunization and serum preparation were as described in Example 1 as except that human recombinant IL-8 was used as an immunogen.
- ELISA assays were performed with respect to the recovered serum, also exactly as described in Example 1, except that the ELISA plates were initially coated using 100 ⁇ l/well of recombinant human IL-8 at 0.5 mg/ml in the coating buffer.
- the results obtained for various serum dilutions from xenomouse A260-5 after 6 injections are shown in FIG. 2 .
- Human anti-IL-8 reactivity was again shown at serum dilutions having concentrations higher than that represented by a 1:1,000 dilution.
- Example 1 Immunization and serum preparation were conducted as described in Example 1 except that human recombinant TNF ⁇ was substituted for human IL-6.
- ELISAs were conducted as described in Example 1 except that the initial coating of the ELISA plate employed 100 ⁇ l/well recombinant human TNF ⁇ at 1 mg/ml in coating buffer.
- the dilution curves for serum from xenomouse A210-8 after 6 injections obtained are shown in FIG. 3 . Again significant titers of human anti-TNF ⁇ reactivity were shown.
- the human CD4 antigen was prepared as a surface protein on transfected recombinant cells as follows: Human CD4 zeta (F15 LTR) as described in Roberts, et al., Blood (1994) 84:2878 was introduced into the rat basophil leukemic cell line RBL-2H3, described by Callan, M., et al., Proc Natl Acad Sci USA (1993) 90:10454 using the kat high efficiency transduction system described by Finer, et al., Blood (1994) 83:43.
- RBL-2H3 cells at 10 6 cells per well were cultured in 750 ml DMEM low +20% FBS (Gibco) and 16 ⁇ g/ml polybrene with an equal volume of proviral supernatant for 2 hours at 37° C., 5% CO 2 .
- One ml of medium was removed and 750 ⁇ l of infection medium and retroviral supernatant were added to each well and the cultures incubated overnight.
- the cells were washed and expanded in DMEM low +10% FBS until sufficient cells were available for sorting.
- the CD4-zeta transduced RBL-2H3 cells were sorted using the FACSTAR plus (Becton Dickinson). The cells were stained for human CD4 with a mouse antihuman CD4-PE antibody and the top 2-3% expressing cells were selected.
- Example 1 Immunizations were conducted as described in Example 1 using 10 ⁇ 10 6 cells per mouse except that the primary injection was subcutaneous at the base of the neck. The mice received 6 injections 2-3 weeks apart. Serum was prepared and analyzed by ELISA as described in Example 1 except that the initial coating of the ELISA plate utilized 100 ⁇ l per well of recombinant soluble CD4 at 2 mg/ml of coating buffer. The titration curve for serum from xenomouse A207-1 after 6 injections is shown in FIG. 4 . Titers of human anti-CD4 reactivity were shown at concentrations representing greater than those at 1:1,000 dilution.
- the antigen was prepared as a surface displayed protein in C51 cells, a high expressing clone derived by transfecting the mouse pre-B cell 300.19 with LAM-1 cDNA (LAM-1 is the gene encoding L-selectin) (Tedder, et al., J Immunol (1990) 144:532) or with similarly transfected CHO cells.
- LAM-1 is the gene encoding L-selectin
- the transfected cells were sorted using fluorescent activated cell sorting using anti-Leu-8 antibody as label.
- the C51 and the transfected CHO cells were grown in DME 4.5 g/l glucose with 10% FCS and 1 mg/ml G418 in 100 mm dishes.
- Negative control cells, 3T3-P317 (transfected with gag/pol/env genes of Moloney virus) were grown in the same medium without G418.
- Sera were collected as described in Example 1 and analyzed by ELISA in a protocol similar to that set forth in Example 1.
- the transfected cells were plated into 96 well plates and cell monolayers grown for 1-2 days depending on cell number and used for ELISA when confluent.
- the cells were fixed by first washing with cold 1 ⁇ PBS and then fixing solution (5% glacial acetic acid, 95% ethanol) was added.
- the plates were incubated at ⁇ 25° C. for 5 minutes and can be stored at this temperature if sealed with plate sealers.
- the ELISA is begun by bringing the plates to room temperature, flicking to remove fixing solution and washing 5 times with DMEM medium containing 10% FCS at 200 ⁇ l per well.
- Positive control wells contained murine IgG1 to human L-selectin.
- ELISAs were also performed using as the immobilized antigen a fusion protein consisting of the extracellular domain of human L-selectin fused to the constant domain of human IgG 1 (Guo, et al., Cell Immunol (1994) 154:202).
- the L-selectin fusion protein was made by transient transfection of human 293 cells using calcium phosphate transfection (Wigler, M., Cell (1979) 16:777). Serum preparation was performed as described in Example 1.
- ELISAs were conducted essentially as in Example 1, except that the initial coating of the ELISA plate employed 100 ⁇ l transfected 293 cell culture supernatant containing the L-selectin-Ig fusion protein. Detection employed HRP-mouse antihuman kappa and HRP-goat antimouse IgG.
- FIG. 7 shows the results from xenomouse A195-2; antibodies specific for L-selectin having human kappa light chains and/or murine heavy chain ⁇ regions are present in the serum.
- the antisera obtained from the immunized xenomice were also tested for staining of human neutrophils.
- Human neutrophils were prepared as follows: peripheral blood was collected from normal volunteers with 100 units/ml heparin. About 3.5 ml blood was layered over an equal volume of One-step Polymorph Gradient (Accurate Chemical, Westbury, N.Y.) and spun for 30 minutes at 450 ⁇ G at 20° C. The neutrophil fraction was removed and washed twice in DPBS/2% FBS.
- the neutrophils were then stained with either:
- the stained, washed neutrophils were analyzed by FACS.
- the results for antiserum from xenomouse A195-2 are shown in FIGS. 8 and 9 .
- these antibodies containing human variable regions are readily convertible to fully human antibodies.
- the cDNAs encoding them can be obtained.
- amplifying the genes encoding human V regions using primers containing restriction enzyme recognition sites and cloning them into plasmids containing the coding sequences for human constant regions as described by Queen, et al., Proc Natl Acad Sci (1989) 86:10029 genes encoding the fully human antibodies can be obtained for recombinant production.
- gp39 (the ligand for CD40) is expressed on activated human CD4+ T cells.
- the sera of xenomice immunized with recombinant gp39 according to this example contained antibodies immunospecific for gp39 with fully human variable regions; the sera contained fully human IgM antibodies and chimeric IgG antibodies containing human variable regions and murine constant heavy chain y region.
- the antigen consisted of stable transfectants of 300.19 cells or of CHO cells expressing gp39 cDNA cloned into the mammalian expression vector P1K1.HUgp39/IRES NEO as shown in FIG. 10 .
- CHO cells were split 1:10 prior to transfection in DMEM 4.5 g/l glucose, 10% FBS, 2 mM glutamine, MEM, NEAA supplemented with additional glycine, hypoxanthine and thymidine.
- the cells were cotransfected with the gp39 vector at 9 ⁇ g/10 cm plate (6 ⁇ 10 5 cells) and the DHFR expressing vector pSV2DHFRs (Subranani et al.
- mice grouped as described in Example 1 were immunized with 300.19 cells expressing gp39 using a primary immunization subcutaneously at the base of the neck and with secondary intraperitoneal injections every 2-3 weeks.
- Sera were harvested as described in Example 1 for the ELISA assay.
- the ELISA procedure was conducted substantially as set forth in Example 1; the microtiter plates were coated with CHOD-gp39 cells grown in a 100 mm dish in DMEM, 4.5 g/l glucose, 10% FCS, 4 mM glutamine, and nonessential amino acid (NEAA) solution for MEM (100 ⁇ ).
- the cells were trypsinized and plated into 96-well filtration plates at 10 5 cells/200 ⁇ l well and incubated at 37° C. overnight.
- the positive controls were mouse antihuman gp39; negative controls were antisera from mice immunized with an antigen other than gp39. 50 ⁇ l of sample were used for each assay. The remainder of the assay is as described in Example 1.
- the dilution curves for the sera obtained after 4 injections from mice immunized with gp39 expressed on CHO cells are shown in FIG. 11 .
- the sera contained antihuman gp39 immunospecificity which is detectable with human kappa and human ⁇ HRP-coupled antibodies.
- PBMC peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin.
- PBMC peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin.
- PBMC peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin.
- PBMC peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin.
- PBMC peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin.
- PBMC were isolated over Ficoll gradient and activated with 3 ⁇ g/ml PHA, 1 ⁇ g/ml PMA in IMDM plus 10% FBS plus 25 ⁇ M 2-mercaptoethanol for 4 hours.
- the PBMC were stained with mouse Mab against human CD4 labeled with FITC to permit separation of activated human T cells from unactivated cells.
- the activated CD4+ and CD4 ⁇ T cells were then analyzed by FACS using staining with either:
- the detecting antibody in the FACS analysis was goat antimouse IgG (PE). The results are shown in FIG. 12 .
- CD4+ (R2) and CD4 ⁇ (R3) cells were separated prior to FACS analysis.
- Panel B shows the results for CD4+ cells and shows that sera from mice immunized with gp39 (labeled A247-4 in the figure) reacted with these activated PBMC;
- panel C shows that these sera did not react with CD4 ⁇ cells.
- These antibodies carried immune heavy chain ⁇ constant regions.
- the results of panels B and C confirm that the TNF-injected xenomouse did not make antibodies against activated human T cells.
- the antibodies prepared in this example were secreted by hybridomas obtained by immortalizing B cells from xenomice immunized with tetanus toxin.
- the immunization protocol was similar to that set forth in Example 1 using 50 ⁇ g tetanus toxin emulsified in complete Freund's adjuvant for intraperitoneal primary immunization followed by subsequent intraperitoneal injections with antigen incorporated into incomplete Freund's adjuvant. The mice received a total of 4 injections 2-3 weeks apart.
- anti-TTC antitetanus toxinC
- the spleen cells were fused with myeloma cells P3 ⁇ 63-Ag8.653 as described by Galfre, G. and Milstein, C. Methods in Enzymology (1981) 73:3-46.
- the cells were resuspended in DMEM, 15% FCS, containing HAT supplemented with glutamine, pen/strep for culture at 37° C. and 10% CO 2 .
- the cells were plated in microtiter trays and maintained in HAT-supplemented medium for two weeks before transfer to HT-supplemented media.
- Supernatants from wells containing hybridomas were collected for a primary screen using an ELISA.
- the ELISA was conducted as described in Example 1 wherein the antigen coating consisted of 100 ⁇ l/well of tetanus toxin C (TTC) protein at 2 mg/ml in coating buffer, followed by incubation at 4° C. overnight or at 37° C. for two hours.
- TTC tetanus toxin C
- HRP-conjugated goat antimouse IgG at 1/2000 was used in addition to HRP mouse antihuman IgM as described in Example 1.
- Two hybridomas that secreted anti-TTC according to the ELISA assay, clone D5.1 and clone K4.1 were used for further analysis.
- clone D5.1 secretes fully human anti-TTC which is detectable using HRP-conjugated antihuman ⁇ and HRP-conjugated antihuman kappa.
- FIG. 14 shows that clone K4.1 secretes anti-TTC which is immunoreactive with antimurine ⁇ and antihuman kappa HRP-conjugated antibodies.
- clone K4.1 provides anti-TTC with human variable regions and a murine constant heavy chain ⁇ region.
- the antibodies secreted by D5.1 and K4.1 did not immunoreact in ELISAs using TNF ⁇ , IL-6, or IL-8 as immobilized antigen under conditions where positive controls (sera from xenomice immunized with TNF ⁇ , IL-6 and IL-8 respectively) showed positive ELISA results.
- TTC TTC antigen
- the surface was activated with 35 ⁇ l of equal volumes 0.1 M NHS and 0.1 M EDC injected across the surface followed by 30 ⁇ l of TTC fragment at 100 ⁇ g/ml in 10 mM sodium acetate buffer pH 5.0. The surface was blocked by injecting 35 ⁇ l 1 M ethanolamine and washed to remove noncovalently bound TCC using 5 ⁇ l 0.1 M HCl. The entire immobilization procedure was conducted with a continuous flow of buffer at 5 ⁇ l/min. This results in about 7500-8500 response units (RU) of TTC per chip. (1000 RU corresponds to about 1 ng of protein per mm2.)
- the procedure utilizes 15 ⁇ l rather than 30 ⁇ l of TTC, resulting in chips containing 550-950 RU.
- Chips could be regenerated after use in single determinations by injecting 10 ⁇ l formal or MgCl 2 .
- the chips are used to determine binding affinities by determining k a and k b (the association and dissociation rate constants) for the antibody with respect to the immobilized TTC.
- the association rate constant is measured over six minutes at a flow rate of 5 ⁇ l/min. at different concentrations of K4.1 Mab in the range of 2.16 nm-69.33 nm.
- the dissociation rate constant is measured at a constant buffer flow rate of 5 ⁇ l/min after completion of the antibody injection.
- the raw data are graphed in FIG. 15 and the calculated results are shown in Table 1. TABLE 1 Kinetic Constants of K4.1 Measured Using the BIAcore on Two Different Surface Association Dissociation Binding Dis Immobilized K4.1 conc.
- the K4.1 antibody has a binding constant for TTC somewhat larger than 10 10 l/mol.
- the complete nucleotide sequence of the cDNAs encoding the heavy and light chains of the K4.1 and D5.1 monoclonals were determined as shown in FIGS. 16-19 .
- PolyA mRNA was isolated from about 10 6 hybridoma cells and used to generate cDNA using random hexamers as primers. Portions of the product were amplified by PCR using the appropriate primers.
- Both cell lines were known to provide human kappa light chains; for PCR amplification of light chain encoding cDNA, the primers used were HKP1 (5′-CTCTGTGACACTCTCCTGGGAGTT-3′) for priming from the constant region terminus and two oligos, used in equal amounts to prime from the variable segments: B3 (5′-CCACCATCAACTGCAAGTCCAGCCA-3′) and B2/B1 (5′-GAAACGACACTCACGCAGTCTCCAGC-3′).
- the primers were MG-24Vi for the human variable regions: 5′-CAGGTGCAGCTGGAGCAGTCiGG-3′ which, with inosine as shown recognizes the human variable regions V H1-2 , V H1-3 , V H4 and V H6 , and from the constant region MG-25 i.e., 5′-GCACACCGCTGGACAGGGATCCAiAGTTTC-3′, which, containing inosine as shown recognizes murine ⁇ 1, ⁇ 2A, ⁇ 2B, and ⁇ 3.
- MG-24VI was used to prime from the variable and ⁇ P1 (5′-TTTTCTTTGTTGCCGTTGGGGTGC-3′) was used to prime from the constant region terminus.
- FIG. 16 representing the heavy chain of the Mab secreted by K4.1
- the sequence shows the presence of the human variable segment VH6, the human diversity region DN1, and the human joining segment JH4 linked to the murine ⁇ 1 constant region.
- VH6 the human variable segment
- DN1 the human diversity region
- JH4 the human joining segment
- FIG. 17 which shows the light chain of the K4.1 antibody
- analysis shows the presence of the human kappa variable region B3 and joining region JK4. Eight nucleotides are missing from B3 at the V K -J K junction and four mutations were found in the variable region. Five nongermline nucleotide additions were present at the V K -J K junction.
- FIG. 18 which sets forth the sequence for the heavy chain of the antibody secreted by clone D5.1, this shows the heavy chain is comprised of the human variable fragment VH6, the human diversity region DN1 and the human joining segment JH4 linked to the human ⁇ constant region.
- VH6 the human variable fragment
- DN1 the human diversity region
- JH4 the human joining segment
- FIG. 19 which presents the light chain of the antibody secreted by D5.1, the human kappa variable region B3 and human kappa joining region JK3 are shown. There are nine base-pair differences from the germline sequences, three falling within CDR1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.
Description
- The invention relates to the field of immunology, and in particular to the production of antibodies. More specifically, it concerns producing such antibodies by a process which includes the step of immunizing a transgenic animal with an antigen to which antibodies are desired. The transgenic animal has been modified so as to produce human, as opposed to endogenous antibodies.
- PCT application WO 94/02602, published 3 Feb. 1994 and incorporated herein by reference, describes in detail the production of transgenic nonhuman animals which are modified so as to produce antibodies with fully human variable regions rather than endogenous antibodies in response to antigenic challenge. Briefly, the endogenous loci encoding the light and heavy immunoglobulin chains are incapacitated in the transgenic hosts and loci encoding human heavy and light chain proteins are inserted into the genome. In general, the animal which provides all the desired modifications is obtained by cross-breeding intermediate animals containing fewer than the full complement of modifications. The preferred embodiment of the nonhuman animal described in the specification is a mouse. Thus., mice, specifically, are described which, when administered immunogens, produce antibodies with human variable regions, including fully human antibodies, rather than murine antibodies that are immunospecific for these antigens.
- The availability of such transgenic animals makes possible new approaches to the production of fully human antibodies. Antibodies with various immunospecificities are desirable for therapeutic and diagnostic use. Those antibodies intended for human therapeutic and in vivo diagnostic use, in particular, have been problematic because prior art sources for such antibodies resulted in immunoglobulins bearing the characteristic structures of antibodies produced by nonhuman hosts. Such antibodies tend to be immunogenic when used in humans.
- The availability of the nonhuman, immunogen-responsive transgenic animals described in the above-referenced WO 94/02602 make possible convenient production of human antibodies without the necessity of employing human hosts.
- The invention is directed to methods to produce human antibodies by a process wherein at least one step of the process includes immunizing a transgenic nonhuman animal with the desired antigen. The modified animal fails to produce endogenous antibodies, but instead produces B-cells which secrete immunoglobulins with fully human variable regions. The antibodies produced include fully human antibodies and can be obtained from the animal directly, or from immortalized B-cells derived from the animal. Alternatively, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly or modified to obtain analogs of antibodies such as, for example, single chain FV molecules.
- Thus, in one aspect, the invention is directed to a method to produce an immunoglobulin with a fully human variable region to a specific antigen or to produce an analog of said immunoglobulin by a process which comprises immunizing a nonhuman animal with the antigen under conditions that stimulate an immune response. The nonhuman animal is characterized by being substantially incapable of producing endogenous heavy or light immunoglobulin chain, but capable of producing immunoglobulins either with both human variable regions and constant regions or with fully human variable regions or both. In the resulting immune response, the animal produces B cells which secrete immunoglobulins, with at least variable regions that are fully human, specific for the antigen. The human immunoglobulin of desired specificity can be directly recovered from the animal, for example, from the serum, or primary B cells can be obtained from the animal and immortalized. The immortalized B cells can be used directly as the source of human antibodies or, alternatively, the genes encoding the antibodies can be prepared from the immortalized B cells or from primary B cells of the blood or lymphoid tissue (spleen, tonsils, lymph nodes, bone marrow) of the immunized animal and expressed in recombinant hosts, with or without modification, to produce the immunoglobulin or its analogs. In addition, the genes encoding the repertoire of immunoglobulins produced by the immunized animal can be used to generate a library of immunoglobulins to permit screening for those variable regions which provide the desired affinity. Clones from the library which have the desired characteristics can then be used as a source of nucleotide sequences encoding the desired variable regions for further manipulation to generate antibodies or analogs with these characteristics using standard recombinant techniques.
- In another aspect, the invention relates to an immortalized nonhuman B cell line derived from the above described animal. In still another aspect, the invention is directed to a recombinant host cell which is modified to contain the gene encoding either the human immunoglobulin with the desired specificity, or an analog thereof which exhibits the same specificity.
- In still other aspects, the invention is directed to antibodies or antibody analogs prepared by the above described methods and to recombinant materials for their production.
- In still other aspects, the invention is directed to antibodies with fully human variable regions, including fully human antibodies which are immunospecific with respect to particular antigens set forth herein and to analogs which are similarly immunospecific, as well as to the recombinant materials useful in the production of these antibodies.
-
FIG. 1 shows the serum titers of anti-IL-6 antibodies from a xenomouse immunized with human IL-6 and which antibodies contain human kappa light chains and/or human μ heavy chains. -
FIG. 2 shows the serum titers of anti-IL-8 antibodies from a xenomouse immunized with human IL-8 and which antibodies contain human kappa light chains and/or human μ heavy chains. -
FIG. 3 shows the serum titers of anti-TNFα antibodies from a xenomouse immunized with human TNF-α and which antibodies contain human kappa light chains and/or human μ heavy chains. -
FIG. 4 shows the serum titers of anti-CD4 antibodies from a xenomouse immunized with human CD4 and which antibodies contain human kappa light chains and/or human μ heavy chains. -
FIG. 5 shows the serum titers of a xenomouse immunized with 300.19 cells expressing L-selectin at their surface. In the ELISA assay used, these antibodies are detectable only if they carry human μconstant region heavy chains. -
FIG. 6 shows the serum titers of a xenomouse immunized with 300.19 cells expressing L-selectin at their surface. In the ELISA assay used, these antibodies are detectable only if they carry human kappa light chains. -
FIG. 7 shows the serum titers of a xenomouse immunized with 300.19 cells expressing L-selectin. In this ELISA, these antibodies are detectable if they carry human kappa light chain and/or murine y constant regions. -
FIG. 8 shows a FACS analysis of human neutrophils coupled to sera from a xenomouse (A195-2) immunized with human L-selectin and labeled with an antibody immunoreactive with murine heavy chain γ constant region. -
FIG. 9 shows a FACS analysis of human neutrophils incubated with serum from a xenomouse (A195-2) immunized with human L-selectin and labeled with an antibody immunoreactive with human light chain kappa region. -
FIG. 10 is a diagram of a plasmid used to transfect mammalian cells to effect the production of the human protein gp39. -
FIG. 11 represents the serum titration curve of mice immunized with CHO cells expressing human gp39. The antibodies detected in this ELISA must be immunoreactive with gp39 and contain human heavy chain μ constant regions or human kappa light chains. -
FIG. 12 shows the results of a FACS analysis of antibodies from a xenomouse (labeled A247-4) immunized with human gp39 reacted with activated human T cells.FIG. 12A shows the separation of human activated T cells into CD4+ and CD4− populations. Panel B shows the results of a FACS analysis of the activated CD4+ T cells with antibodies from the xenomouse immunized with gp39 which contain murine heavy chain γ constant regions; panel C shows the corresponding results with respect to CD4− populations. -
FIG. 13 is a titration curve with respect to monoclonal antibodies secreted by the hybridoma clone D5.1. This clone is obtained from a xenomouse immunized with tetanus toxin C (TTC) and contains human kappa light chain and human μ constant region in the heavy chain. -
FIG. 14 is a titration curve with respect to the hybridoma supernatant from clone K4.1. This hybridoma clone is obtained from a xenomouse immunized with TTC and contains human kappa light chain and heavy chain having the murine γ constant region. -
FIG. 15 shows binding curves for various concentrations of the K4.1 monoclonal antibody in a determination of the affinity of the monoclonal with its antigen in a BIAcore instrument. -
FIG. 16 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by K4.1. -
FIG. 17 shows the complete nucleotide sequence of the light chain from the antibody secreted by K4.1. -
FIG. 18 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by D5.1. -
FIG. 19 shows the complete nucleotide sequence of the light chain from the antibody secreted by D5.1. - In general, the methods of the invention include administering an antigen for which human forms of immunospecific reagents are desired to a transgenic nonhuman animal which has been modified genetically so as to be capable of producing human, but not endogenous, antibodies. Typically, the animal has been modified to disable the endogenous heavy and/or light chain loci in its genome, so that these endogenous loci are incapable of the rearrangement required to generate genes encoding immunoglobulins in response to an antigen. In addition, the animal will have been provided, stably, in its genome, at least one human heavy chain locus and at least one human light chain locus so that in response to an administered antigen, the human loci can rearrange to provide genes encoding human immunoglobulins immunospecific for the antigen.
- The details for constructing such an animal useful in the method of the invention are provided in the PCT application WO 94/02602 referenced above.
- For production of the desired antibodies, the first step is administration of the antigen. Techniques for such administration are conventional and involve suitable immunization protocols and formulations which will depend on the nature of the antigen per se. It may be necessary to provide the antigen with a carrier to enhance its immunogenicity and/or to include formulations which contain adjuvants and/or to administer multiple injections, and the like. Such techniques are standard and optimization of them will depend on the characteristics of the particular antigen for which immunospecific reagents are desired.
- As used herein, the term “immunospecific reagents” includes immunoglobulins and their analogs. The term “analogs” has a specific meaning in this context. It refers to moieties that contain the fully human portions of the immunoglobulin which account for its immunospecificity. In particular, variable regions including the complementarity determining regions (CDRs) are required, along with sufficient portions of the framework regions (FRs) to result in the appropriate three dimensional conformation. Typical immunospecific analogs of antibodies include F(ab′)
2 , Fab′, and Fab regions. Modified forms of the variable regions to obtain, for example, single chain FV analogs with the appropriate immunospecificity are known. A review of such FV construction is found, for example, in Tibtech (1991) 9:______. The construction of antibody analogs with multiple immunospecificities is also possible by coupling the human variable regions derived from antibodies with varying specificities. - The variable regions with fully human characteristics can also be coupled to a variety of additional substances which can provide toxicity, biological functionality, alternative binding specificities and the like. The moieties including the fully human variable regions produced by the methods of the invention include single-chain fusion proteins, molecules coupled by covalent methods other than those involving peptide linkages, and aggregated molecules. Examples of analogs which include variable regions coupled to additional molecules covalently or noncovalently include those in the following nonlimiting illustrative list. Traunecker, A. et al. Int J Cancer Supp (1992) Supp 7:51-52 describe the bispecific reagent janusin in which the FV region directed to CD3 is coupled to soluble CD4 or to other ligands such as OVCA and IL-7. Similarly, the fully human variable regions produced by the method of the invention can be constructed into FV molecules and coupled to alternative ligands such as those illustrated in the cited article. Higgins, P. J. et al. J Infect Disease (1992) 166:198-202 describe a heteroconjugate antibody composed of OKT3 cross-linked to an antibody directed to a specific sequence in the V3 region or GP120. Such heteroconjugate antibodies can also be constructed using at least the human variable regions contained in the immunoglobulins produced by the invention methods. Additional examples of bispecific antibodies include those described by Fanger, M. W. et al. Cancer Treat Res (1993) 68:181-194 and by Fanger, M. W. et al. Crit Rev Immunol (1992) 12:101-124. Conjugates that are immunotoxins including conventional antibodies have been widely described in the art. The toxins may be coupled to the antibodies by conventional coupling techniques or immunotoxins containing protein toxin portions can be produced as fusion proteins. The analogs of the present invention can be used in a corresponding way to obtain such immunotoxins. Illustrative of such immunotoxins are those described by Byrs, B. S. et al. Seminars Cell Biol (1991) 2:59-70 and by Fanger, M. W. et al. Immunol Today (1991) 12:51-54.
- In short, the genes encoding the immunoglobulins produced by the transgenic animals of the invention can be retrieved and the nucleotide sequences encoding the fully human variable region can be manipulated according to known techniques to provide a variety of analogs such as those described above. In addition, the immunoglobulins themselves containing the human variable regions can be modified using standard coupling techniques to provide conjugates retaining immunospecificity and fully human characteristics in the immunospecific region.
- Thus, immunoglobulin “analogs” refers to moieties which contain those portions of the antibodies of the invention which retain their human characteristics and their immunospecificity. These will retain sufficient human variable region to provide the desired specificity.
- As stated above, all of the methods of the invention include administering the appropriate antigen to the transgenic animal. The recovery or production of the antibodies themselves can be achieved in various ways.
- First, and most straightforward, the polyclonal antibodies produced by the animal and secreted into the bloodstream can be recovered using known techniques. Purified forms of these antibodies can, of course, be readily prepared by standard purification techniques, preferably including affinity chromatography with respect to the particular antigen, or even with respect to the particular epitope of the antigen for which specificity is desired. In any case, in order to monitor the success of immunization, the antibody levels with respect to the antigen in serum will be monitored using standard techniques such as ELISA, RIA and the like.
- It will be noted, from the examples below, that a portion of the polyclonal antiserum obtained may include an endogenous heavy chain constant region derived from the host, even though the variable regions are fully human. Under these circumstances, to the extent that an application requires fully human antibodies, use of the polyclonal antiserum directly would be inappropriate. However, the presence of these chimeras, which is believed to result from in vivo isotype switching as described by Gerstein et al. Cell (1990) 63:537, is not problematic, in view of conventional purification and modification methods and in view of the availability of alternative methods to recover fully human antibodies, if desired, described in the following paragraphs.
- First, and most simply, the polyclonal antiserum could be subjected to suitable separation techniques to provide compositions containing only fully human immunoglobulins. Portions of the serum which display characteristics of the host species can be removed, for example, using affinity reagents with the appropriate anti species immunoglobulins or immunospecific portions thereof. Furthermore, for applications where only the variable regions of the antibodies are required, treating the polyclonal antiserum with suitable reagents so as to generate Fab, Fab′, or F(ab′)
2 portions results in compositions containing fully human characteristics. Such fragments are sufficient for use, for example, in immunodiagnostic procedures involving coupling the immunospecific portions of immunoglobulins to detecting reagents such as radioisotopes. Thus, for some applications, the polyclonal antiserum can be treated to provide compositions with the desired characteristics including compositions consisting essentially of fully human antibodies and compositions including immunoglobulin analogs wherein the immunospecific portion is fully human. - Alternatively, immunoglobulins and analogs with desired characteristics can be generated from immortalized B cells derived from the transgenic animals used in the method of the invention or from the rearranged genes provided by these animals in response to immunization. It will be apparent that hybridomas derived from the B cells of the immunized animal can be screened so as to choose only those secreting fully human antibodies and that the genetic material can be recovered from the hybridomas or from lymphocytes in spleen, blood, or lymph nodes of the immunized animal and manipulated using conventional techniques to replace any endogenous constant region with a human one or to produce a desired analog.
- Thus, as an alternative to harvesting the antibodies directly from the animal, the B cells can be obtained, typically from the spleen, but also, if desired, from the peripheral blood lymphocytes or lymph nodes and immortalized using any of a variety of techniques, most commonly using the fusion methods described by Kohler and Milstein. The resulting hybridomas (or otherwise immortalized B cells) can then be cultured as single colonies and screened for secretion of antibodies of the desired specificity. As described above, the screen can also include a determination of the fully human character of the antibody. For example, as described in the examples below, a sandwich ELISA wherein the monoclonal in the hybridoma supernatant is bound both to antigen and to an antihuman constant region can be employed. Conversely, hybridomas that secrete antibodies which are immunoreactive with antispecies antibodies directed to the species of the immunized animal can be discarded. After the appropriate hybridomas are selected, the desired antibodies can be recovered, again using conventional techniques. They can be prepared in quantity by culturing the immortalized B cells using conventional methods, either in vitro, or in vivo to produce ascites fluid. Purification of the resulting monoclonal antibody preparations is less burdensome than in the case of serum since each immortalized colony will secrete only a single type of antibody. In any event, standard purification techniques to isolate the antibody from other proteins in the culture medium can be employed.
- As an alternative to obtaining human immunoglobulins directly from the culture of immortalized B cells derived from the animal, the immortalized cells can be used as a source of rearranged heavy chain and light chain loci for subsequent expression and/or genetic manipulation. Isolation of genes from such antibody-producing cells is straightforward since high levels of the appropriate mRNAs are available for production of a cDNA library. The recovered rearranged loci can be manipulated as desired. For example, the constant region can be exchanged for that of a different isotype or that of a human antibody, as described above, or eliminated altogether. The variable regions can be linked to encode single chain FV regions. Multiple FV regions can be linked to confer binding ability to more than one target or chimeric heavy and light chain combinations can be employed. Once the genetic material is available, design of analogs as described above which retain their ability to bind the desired target, as well as their human characteristics, is straightforward.
- Once the appropriate genetic material is obtained and, if desired, modified to encode an analog, the coding sequences including those that encode, at a minimum, the variable regions of the human heavy and light chain can be inserted into expression systems contained on vectors which can be transfected into standard recombinant host cells. As described below, a variety of such host cells may be used; for efficient processing, however, mammalian cells are preferred. Typical mammalian cell lines useful for this purpose include CHO cells, 293 cells, or NSO-GS cells.
- The production of the antibody or analog is then undertaken by culturing the modified recombinant host under culture conditions appropriate for the growth of the host cells and the expression of the coding sequences. The antibodies are then recovered from the culture. The expression systems are preferably designed to include signal peptides so that the resulting antibodies are secreted into the medium; however, intracellular production is also possible.
- In addition to deliberate design of modified forms of the immunoglobulin genes to produce analogs, advantage can be taken of phage display techniques to provide libraries containing a repertoire of antibodies with varying affinities for the desired antigen. For production of such repertoires, it is unnecessary to immortalize the B cells from the immunized animal; rather the primary B cells can be used directly as a source of DNA. The mixture of cDNAs obtained from B cells, e.g., derived from spleens, is used to prepare an expression library, for example, a phage display library transfected into E. coli. The resulting cells are tested for immunoreactivity to the desired antigen. Techniques for the identification of high affinity human antibodies from such libraries are described by Griffiths, A. D., et al., EMBO J (1994) 13:3245-3260; by Nissim, A., et al. ibid,. 692-698, and by Griffiths, A. D., et al., ibid, 725-734. Ultimately, clones from the library are identified which produce binding affinities of a desired magnitude for the antigen, and the DNA encoding the product responsible for such binding is recovered and manipulated for standard recombinant expression. Phage display libraries may also be constructed using previously manipulated nucleotide sequences and screened in similar fashion. In general, the cDNAs encoding heavy and light chain are independently supplied or are linked to form FV analogs for production in the phage library.
- The phage library is thus screened for the antibodies with highest affinity for the antigen and the genetic material recovered from the appropriate clone. Further rounds of screening can increase the affinity of the original antibody isolated. The manipulations described above for recombinant production of the antibody or modification to form a desired analog can then be employed.
- As above, the modified or unmodified rearranged loci are manipulated using standard recombinant techniques by constructing expression systems operable in a desired host cell, such as, typically, a Chinese hamster ovary cell, and the desired immunoglobulin or analog is produced using standard recombinant expression techniques, and recovered and purified using conventional methods.
- The application of the foregoing processes to antibody production has enabled the preparation of human immunospecific reagents with respect to antigens for which human antibodies have not heretofore been available. The immunoglobulins that result from the above-described methods and the analogs made possible thereby, provide novel compositions for use in analysis, diagnosis, research, and therapy. The particular use will, of course, depend on the immunoglobulin or analog prepared. In general, the compositions of the invention will have utilities similar to those ascribable to nonhuman antibodies directed against the same antigen. Such utilities include, for example, use as a affinity ligands for purification, as reagents in immunoassays, as components of immunoconjugates, and as therapeutic agents for appropriate indications.
- Particularly in the case of therapeutic agents or diagnostic agents for use in vivo, it is highly advantageous to employ antibodies or their analogs with fully human characteristics. These reagents avoid the undesired immune responses engendered by antibodies or analogs which have characteristics marking them as originating from non-human species. Other attempts to “humanize” antibodies do not result in reagents with fully human characteristics. For example, chimeric antibodies with murine variable regions and human constant regions are easily prepared, but, of course, retain murine characteristics in the variable regions. Even the much more difficult procedure of “humanizing” the variable regions by manipulating the genes encoding the amino acid sequences that form the framework regions does not provide the desired result since the CDRs, typically of nonhuman origin, cannot be manipulated without destroying immunospecificity. Thus, the methods of the present invention provide, for the first time, immunoglobulins that are fully human or analogs which contain immunospecific regions with fully human characteristics.
- There are large numbers of antigens for which human antibodies and their human analogs would be made available by the methods of the invention. These include the following as a nonlimiting set:
-
- leukocyte markers, such as CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a,b,c, CD13, CD14, CD18, CD19, CD20, CD22. CD23. CD27 and its liqand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and isoforms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1 and TCR
- histocompatibility antigens, such as MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
- integrins, such as VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, and LFA-1;
- adhesion molecules, such as Mac-1 and p150, 95;
- selectins, such as L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, and LFA-3;
- interleukins, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-ll, IL-12, IL-13, IL-14, and IL-15;
- interleukin receptors, such as IL-1R, IL-2R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
- chemokines, such as PF4, RANTES, MIPla, MCP1, NAP-2, Groα, Groβ, and IL-8;
- growth factors, such as TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
- growth factor receptors, such as TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
- interferon receptors, such as IFNαR, IFNβR, and IFNγR;
- Igs and their receptors, such as IgE, FceRI, and FCeR11;
- tumor antigens, such as her2-neu, mucin, CEA and endosialin;
- allergens, such as house dust mite antigen, lol p1 (grass) antigens, and urushiol;
- viral proteins, such as CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
- toxins, such as pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
- blood factors, such as complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor;
- enzymes, such as cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD); and
- miscellaneous antigens including ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV collagen, glycated lipids, γ-interferon, A7, P-glycoprotein and Fas (AFO-1) and oxidized-LDL.
- Particularly preferred immunoglobulins and analogs are those immunospecific with respect to human IL-6, human IL-8, human TNFα, human CD4, human L-selectin, and human gp39. Human antibodies against IL-8 are particularly useful in preventing tumor metastasis and inflammatory states such as asthma. Antibodies and analogs immunoreactive with human TNFα and human IL-6 are useful in treating cachexia and septic shock as well as autoimmune disease. Antibodies and analogs immunoreactive with gp39 or with L-selectin are also effective in treating or preventing autoimmune disease. In addition, anti-gp39 is helpful in treating graft versus host disease, in preventing organ transplant rejection, and in treating glomerulonephritis. Antibodies and analogs against L-selectin are useful in treating ischemia associated with reperfusion injury.
- Typical autoimmune diseases which can be treated using the above-mentioned antibodies and analogs include systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Sjogren's, scleroderma, mixed connective tissue disease, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease,
Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, myasthenia gravis and pemphigus. - The examples below are intended to illustrate but not to limit the invention.
- In these examples, mice, designated “xenomice”, are used for initial immunizations. A detailed description of such xenomice is found in the above referenced PCT application WO 94/02602. Immunization protocols appropriate to each antigen-are described in the specific examples below. The sera of the immunized xenomice (or the supernatants from immortalized B cells) were titrated for antigen specific human antibodies in each case using a standard ELISA format. In this format, the antigen used for immunization was immobilized onto wells of microtiter plates. The plates were washed and blocked and the sera (or supernatants) were added as serial dilutions for 1-2 hours of incubation. After washing bound antibody having human characteristics was detected by adding the appropriate antispecies Ig (typically antihuman kappa or antihuman μ) conjugated to horseradish peroxidase (HRP) for one hour. In some cases, the bound antibodies were tested for murine characteristics using antimurine antibodies, typically antimurine γ. After again washing, the chromogenic reagent o-phenylene diamine (OPD) substrate and hydrogen peroxide were added and the plates were read 30 minutes later at 492=m using a microplate reader.
- Unless otherwise noted, the antigen was coated using plate coating buffer (0.1 M carbonate buffer, pH 9.6); the assay blocking buffer used was 0.5% BSA, 0.1
% Tween 20 and 0.01% Thimerosal in PBS; the substrate buffer used in color development was citric acid 7.14 g/l: dibasic sodium phosphate 17.96 g/l; the developing solution (made immediately before use) was 10 ml substrate buffer, 10 mg OPD, plus 5 ml hydrogen peroxide; the stop solution (used to stop color development) was 2 M sulfuric acid. The wash solution was 0.05% Tween 20 in PBS. - Three to 5 xenomice aged 8-20 weeks were age-matched and immunized intraperitoneally with 50 μg human IL-6 emulsified in complete Freund's adjuvant for primary immunization and in incomplete Freund's adjuvant for subsequent injections. The mice received 6 injections 2-3 weeks apart. Serum titers were determined after the second dose and following each dose thereafter. Bleeds were performed 6-7 days after injections from the retrobulbar plexus. The blood was allowed to clot at room temperature for about 2 hours and then incubated at 4° C. for at least 2 hours before separating and collecting the sera.
- ELISAs were conducted as described above by applying 100 μl per well of recombinant human IL-6 at 2 mg/ml in coating buffer. Plates were then incubated at 4° C. overnight or at 37° C. for 2 hours and then washed three times in washing buffer. Addition of 100 μl/well blocking buffer was followed by incubation at room temperature for 2 hours, and an additional 3 washes.
- Then, 50 μl/well of diluted serum samples (and positive and negative controls) were added to the plates. Plates were then incubated at room temperature for 2 hours and again washed 3 times.
- After washing, 100 μl per well of either HRP-mouse antihuman IgM at 1/2,000 or HRP-mouse antihuman kappa at 1/2,000, diluted in blocking buffer were added. After a 1 hour incubation at room temperature, the plates were washed 3 times and developed with OPD substrate for 10-25 minutes. 50 μl/well of stop solution were then added and the results read on an ELISA plate reader at 492 nm. The dilution curves resulting from the titration of serum from xenomouse A40-7 after 6 injections are shown in
FIG. 1 . The data inFIG. 1 show production of anti-IL-6 immunoreactive with antihuman kappa and antihuman μ detectable at serum dilutions above 1:1,000. - Immunization and serum preparation were as described in Example 1 as except that human recombinant IL-8 was used as an immunogen.
- ELISA assays were performed with respect to the recovered serum, also exactly as described in Example 1, except that the ELISA plates were initially coated using 100 μl/well of recombinant human IL-8 at 0.5 mg/ml in the coating buffer. The results obtained for various serum dilutions from xenomouse A260-5 after 6 injections are shown in
FIG. 2 . Human anti-IL-8 reactivity was again shown at serum dilutions having concentrations higher than that represented by a 1:1,000 dilution. - Immunization and serum preparation were conducted as described in Example 1 except that human recombinant TNFα was substituted for human IL-6. ELISAs were conducted as described in Example 1 except that the initial coating of the ELISA plate employed 100 μl/well recombinant human TNFα at 1 mg/ml in coating buffer.
- The dilution curves for serum from xenomouse A210-8 after 6 injections obtained are shown in
FIG. 3 . Again significant titers of human anti-TNFα reactivity were shown. - The human CD4 antigen was prepared as a surface protein on transfected recombinant cells as follows: Human CD4 zeta (F15 LTR) as described in Roberts, et al., Blood (1994) 84:2878 was introduced into the rat basophil leukemic cell line RBL-2H3, described by Callan, M., et al., Proc Natl Acad Sci USA (1993) 90:10454 using the kat high efficiency transduction system described by Finer, et al., Blood (1994) 83:43. Briefly, RBL-2H3 cells at 106 cells per well were cultured in 750 ml DMEMlow+20% FBS (Gibco) and 16 μg/ml polybrene with an equal volume of proviral supernatant for 2 hours at 37° C., 5% CO2. One ml of medium was removed and 750 μl of infection medium and retroviral supernatant were added to each well and the cultures incubated overnight. The cells were washed and expanded in DMEMlow+10% FBS until sufficient cells were available for sorting. The CD4-zeta transduced RBL-2H3 cells were sorted using the FACSTAR plus (Becton Dickinson). The cells were stained for human CD4 with a mouse antihuman CD4-PE antibody and the top 2-3% expressing cells were selected.
- Immunizations were conducted as described in Example 1 using 10×106 cells per mouse except that the primary injection was subcutaneous at the base of the neck. The mice received 6 injections 2-3 weeks apart. Serum was prepared and analyzed by ELISA as described in Example 1 except that the initial coating of the ELISA plate utilized 100 μl per well of recombinant soluble CD4 at 2 mg/ml of coating buffer. The titration curve for serum from xenomouse A207-1 after 6 injections is shown in
FIG. 4 . Titers of human anti-CD4 reactivity were shown at concentrations representing greater than those at 1:1,000 dilution. - The antigen was prepared as a surface displayed protein in C51 cells, a high expressing clone derived by transfecting the mouse pre-B cell 300.19 with LAM-1 cDNA (LAM-1 is the gene encoding L-selectin) (Tedder, et al., J Immunol (1990) 144:532) or with similarly transfected CHO cells. The transfected cells were sorted using fluorescent activated cell sorting using anti-Leu-8 antibody as label.
- The C51 and the transfected CHO cells were grown in DME 4.5 g/l glucose with 10% FCS and 1 mg/ml G418 in 100 mm dishes. Negative control cells, 3T3-P317 (transfected with gag/pol/env genes of Moloney virus) were grown in the same medium without G418.
- Primary immunization was by injection subcutaneously at the base of the neck; subsequent injections were intraperitoneal. 70-100 million C51 or transfected CHO cells were used per injection for a total of five injections 2-3 weeks apart.
- Sera were collected as described in Example 1 and analyzed by ELISA in a protocol similar to that set forth in Example 1.
- For the ELISA, the transfected cells were plated into 96 well plates and cell monolayers grown for 1-2 days depending on cell number and used for ELISA when confluent. The cells were fixed by first washing with cold 1×PBS and then fixing solution (5% glacial acetic acid, 95% ethanol) was added. The plates were incubated at −25° C. for 5 minutes and can be stored at this temperature if sealed with plate sealers.
- The ELISA is begun by bringing the plates to room temperature, flicking to remove fixing solution and washing 5 times with DMEM medium containing 10% FCS at 200 μl per well.
- The wells were treated with various serum dilutions or with positive or negative controls. Positive control wells contained murine IgG1 to human L-selectin.
- The wells were incubated for 45 minutes and monolayer integrity was checked under a microscope. The wells were then incubated with either HRP-antimouse IgG (1/1000) or with the antihuman kappa or antihuman μ conjugates described in Example 1. The plates were then washed with 1% BSA/PBS and again with PBS and monolayer integrity was checked. The plates were developed, stopped, and read as described above. The results for serum from xenomouse A303-3 are shown in
FIGS. 5 and 6 ; human antibodies both to L-selectin and control 3T3 cells were obtained. However, the serum titers are higher for the L-selectin-expressing cells as compared to parental 3T3 cells. These results show that xenomouse A303-3 produces antibodies specific for L-selectin with human μ heavy chain regions and/or human kappa light chains. - ELISAs were also performed using as the immobilized antigen a fusion protein consisting of the extracellular domain of human L-selectin fused to the constant domain of human IgG1 (Guo, et al., Cell Immunol (1994) 154:202). The L-selectin fusion protein was made by transient transfection of human 293 cells using calcium phosphate transfection (Wigler, M., Cell (1979) 16:777). Serum preparation was performed as described in Example 1. ELISAs were conducted essentially as in Example 1, except that the initial coating of the ELISA plate employed 100 μl transfected 293 cell culture supernatant containing the L-selectin-Ig fusion protein. Detection employed HRP-mouse antihuman kappa and HRP-goat antimouse IgG.
-
FIG. 7 shows the results from xenomouse A195-2; antibodies specific for L-selectin having human kappa light chains and/or murine heavy chain γ regions are present in the serum. - The antisera obtained from the immunized xenomice were also tested for staining of human neutrophils. Human neutrophils were prepared as follows: peripheral blood was collected from normal volunteers with 100 units/ml heparin. About 3.5 ml blood was layered over an equal volume of One-step Polymorph Gradient (Accurate Chemical, Westbury, N.Y.) and spun for 30 minutes at 450×G at 20° C. The neutrophil fraction was removed and washed twice in DPBS/2% FBS.
- The neutrophils were then stained with either:
-
- (1) antiserum from xenomouse A195-2 immunized with C51 cells (expressing L-selectin);
- (2) as a positive control, mouse monoclonal antibody LAM1-3 (against L-selectin); and
- (3) as negative control, antiserum from a xenomouse immunized with cells expressing human gp39.
- The stained, washed neutrophils were analyzed by FACS. The results for antiserum from xenomouse A195-2 are shown in
FIGS. 8 and 9 . - These results show the presence of antibodies in immunized xenomouse serum which contain fully human variable regions immunoreactive with L-selectin. The negative control antiserum from mice immunized with gp39 does not contain antibodies reactive against human neutrophils. Serum from A195-2 (immunized with L-selectin-expressing cells) contains antibodies binding to human neutrophils detectable with a goat antimouse IgG (
FIG. 8 ), which immunoreacts with heavy chain protein composed of fully human variable regions and mouse γ constant regions. Staining with anti L-selectin xenomouse antisera detected with a mouse monoclonal antibody against human kappa is shown inFIG. 9 , showing the presence of fully human kappa light chain. - As explained above, these antibodies containing human variable regions are readily convertible to fully human antibodies. For example, using hybridomas secreting these antibodies, the cDNAs encoding them can be obtained. By amplifying the genes encoding human V regions using primers containing restriction enzyme recognition sites and cloning them into plasmids containing the coding sequences for human constant regions as described by Queen, et al., Proc Natl Acad Sci (1989) 86:10029, genes encoding the fully human antibodies can be obtained for recombinant production.
- gp39 (the ligand for CD40) is expressed on activated human CD4+ T cells. The sera of xenomice immunized with recombinant gp39 according to this example contained antibodies immunospecific for gp39 with fully human variable regions; the sera contained fully human IgM antibodies and chimeric IgG antibodies containing human variable regions and murine constant heavy chain y region.
- The antigen consisted of stable transfectants of 300.19 cells or of CHO cells expressing gp39 cDNA cloned into the mammalian expression vector P1K1.HUgp39/IRES NEO as shown in
FIG. 10 . CHO cells were split 1:10 prior to transfection in DMEM 4.5 g/l glucose, 10% FBS, 2 mM glutamine, MEM, NEAA supplemented with additional glycine, hypoxanthine and thymidine. The cells were cotransfected with the gp39 vector at 9 μg/10 cm plate (6×105 cells) and the DHFR expressing vector pSV2DHFRs (Subranani et al. Mol Cell Biol (1981) 9:854) at 1 μg/10 cm plate using calcium phosphate transfection. 24 hours later the cells were split 1:10 into the original medium containing G418 at 0.6 mg/ml. Cells producing gp39 were sorted by FACS using an anti-gp39 antibody. - Mice grouped as described in Example 1 were immunized with 300.19 cells expressing gp39 using a primary immunization subcutaneously at the base of the neck and with secondary intraperitoneal injections every 2-3 weeks. Sera were harvested as described in Example 1 for the ELISA assay. The ELISA procedure was conducted substantially as set forth in Example 1; the microtiter plates were coated with CHOD-gp39 cells grown in a 100 mm dish in DMEM, 4.5 g/l glucose, 10% FCS, 4 mM glutamine, and nonessential amino acid (NEAA) solution for MEM (100×). On the day preceding the ELISA assay, the cells were trypsinized and plated into 96-well filtration plates at 105 cells/200 μl well and incubated at 37° C. overnight. The positive controls were mouse antihuman gp39; negative controls were antisera from mice immunized with an antigen other than gp39. 50 μl of sample were used for each assay. The remainder of the assay is as described in Example 1.
- The dilution curves for the sera obtained after 4 injections from mice immunized with gp39 expressed on CHO cells are shown in
FIG. 11 . As shown, the sera contained antihuman gp39 immunospecificity which is detectable with human kappa and human μ HRP-coupled antibodies. - In addition, the sera were tested for their ability to react with activated human T cells included in PBMC using FACS analysis. To prepare the PBMC, human peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin. PBMC were isolated over Ficoll gradient and activated with 3 μg/ml PHA, 1 μg/ml PMA in IMDM plus 10% FBS plus 25 μM 2-mercaptoethanol for 4 hours. After washing, the PBMC were stained with mouse Mab against human CD4 labeled with FITC to permit separation of activated human T cells from unactivated cells.
- The activated CD4+ and CD4−T cells were then analyzed by FACS using staining with either:
-
- 1) antiserum from a Xenomouse immunized with 300.19 cells producing gp39;
- 2) a positive control mouse Mab directed against a-CD40L (human gp39); and
- 3) a negative control antiserum from a Xenomouse immunized with TNF.
- The detecting antibody in the FACS analysis was goat antimouse IgG (PE). The results are shown in
FIG. 12 . - As shown in
FIG. 12A , CD4+ (R2) and CD4− (R3) cells were separated prior to FACS analysis. Panel B shows the results for CD4+ cells and shows that sera from mice immunized with gp39 (labeled A247-4 in the figure) reacted with these activated PBMC; panel C shows that these sera did not react with CD4− cells. These antibodies carried immune heavy chain γ constant regions. The results of panels B and C confirm that the TNF-injected xenomouse did not make antibodies against activated human T cells. - The antibodies prepared in this example were secreted by hybridomas obtained by immortalizing B cells from xenomice immunized with tetanus toxin. The immunization protocol was similar to that set forth in Example 1 using 50 μg tetanus toxin emulsified in complete Freund's adjuvant for intraperitoneal primary immunization followed by subsequent intraperitoneal injections with antigen incorporated into incomplete Freund's adjuvant. The mice received a total of 4 injections 2-3 weeks apart.
- After acceptable serum titers of antitetanus toxinC (anti-TTC) were obtained, a final dose of antigen in PBS was given 4 days before the animals were sacrificed and the spleens harvested for fusion.
- The spleen cells were fused with myeloma cells P3×63-Ag8.653 as described by Galfre, G. and Milstein, C. Methods in Enzymology (1981) 73:3-46.
- After fusion the cells were resuspended in DMEM, 15% FCS, containing HAT supplemented with glutamine, pen/strep for culture at 37° C. and 10% CO2. The cells were plated in microtiter trays and maintained in HAT-supplemented medium for two weeks before transfer to HT-supplemented media. Supernatants from wells containing hybridomas were collected for a primary screen using an ELISA.
- The ELISA was conducted as described in Example 1 wherein the antigen coating consisted of 100 μl/well of tetanus toxin C (TTC) protein at 2 mg/ml in coating buffer, followed by incubation at 4° C. overnight or at 37° C. for two hours. In the primary ELISA, HRP-conjugated goat antimouse IgG at 1/2000 was used in addition to HRP mouse antihuman IgM as described in Example 1. Two hybridomas that secreted anti-TTC according to the ELISA assay, clone D5.1 and clone K4.1 were used for further analysis.
- As shown in
FIG. 13 , clone D5.1 secretes fully human anti-TTC which is detectable using HRP-conjugated antihuman μ and HRP-conjugated antihuman kappa.FIG. 14 shows that clone K4.1 secretes anti-TTC which is immunoreactive with antimurine γ and antihuman kappa HRP-conjugated antibodies. Thus, clone K4.1 provides anti-TTC with human variable regions and a murine constant heavy chain γ region. - The antibodies secreted by D5.1 and K4.1 did not immunoreact in ELISAs using TNFα, IL-6, or IL-8 as immobilized antigen under conditions where positive controls (sera from xenomice immunized with TNFα, IL-6 and IL-8 respectively) showed positive ELISA results.
- The affinity of the monoclonal antibodies secreted by K4.1 for TTC antigen was determined using commercially available reagents and instrumentation. BIAcore Instrument, CM5 sensor chips, surfactant P20 and the amine coupling kit were purchased from Pharmacia Biosensor (Piscataway, N.J.). TTC was immobilized at two levels of antigen density on the surface of the sensor chips according to the manufacturer's instructions. Briefly, after washing and equilibrating the instrument with buffer containing surfactant, the surfaces were activated and the TCC was immobilized.
- For high antigen density, the surface was activated with 35 μl of equal volumes 0.1 M NHS and 0.1 M EDC injected across the surface followed by 30 μl of TTC fragment at 100 μg/ml in 10 mM sodium acetate buffer pH 5.0. The surface was blocked by injecting 35 μl 1 M ethanolamine and washed to remove noncovalently bound TCC using 5 μl 0.1 M HCl. The entire immobilization procedure was conducted with a continuous flow of buffer at 5 μl/min. This results in about 7500-8500 response units (RU) of TTC per chip. (1000 RU corresponds to about 1 ng of protein per mm2.)
- For chips with low antigen density, the procedure utilizes 15 μl rather than 30 μl of TTC, resulting in chips containing 550-950 RU.
- Chips could be regenerated after use in single determinations by injecting 10 μl formal or MgCl2.
- The chips are used to determine binding affinities by determining ka and kb (the association and dissociation rate constants) for the antibody with respect to the immobilized TTC. The association rate constant is measured over six minutes at a flow rate of 5 μl/min. at different concentrations of K4.1 Mab in the range of 2.16 nm-69.33 nm. The dissociation rate constant is measured at a constant buffer flow rate of 5 μl/min after completion of the antibody injection. The raw data are graphed in
FIG. 15 and the calculated results are shown in Table 1.TABLE 1 Kinetic Constants of K4.1 Measured Using the BIAcore on Two Different Surface Association Dissociation Binding Dis Immobilized K4.1 conc. rate rate constant c tetanus toxinC range nM ka(105 M−1s−1) kd(105s−1) KA(M−1) = ka/kd KD 5931 RU 4.3-34.7 6.47 ± 1.05 4.02 ± 1.42 1.6 × 1010 0.6 868 RU 4.3-34.7 7.19 ± 2.18 2.02 ± 1.01 3.5 × 1010 0.2 - As shown, the K4.1 antibody has a binding constant for TTC somewhat larger than 1010 l/mol.
- The complete nucleotide sequence of the cDNAs encoding the heavy and light chains of the K4.1 and D5.1 monoclonals were determined as shown in
FIGS. 16-19 . PolyA mRNA was isolated from about 106 hybridoma cells and used to generate cDNA using random hexamers as primers. Portions of the product were amplified by PCR using the appropriate primers. - Both cell lines were known to provide human kappa light chains; for PCR amplification of light chain encoding cDNA, the primers used were HKP1 (5′-CTCTGTGACACTCTCCTGGGAGTT-3′) for priming from the constant region terminus and two oligos, used in equal amounts to prime from the variable segments: B3 (5′-CCACCATCAACTGCAAGTCCAGCCA-3′) and B2/B1 (5′-GAAACGACACTCACGCAGTCTCCAGC-3′).
- For amplification of the heavy chain from K4.1 (which contains the murine γ1 constant region), the primers were MG-24Vi for the human variable regions: 5′-CAGGTGCAGCTGGAGCAGTCiGG-3′ which, with inosine as shown recognizes the human variable regions VH1-2, VH1-3, VH4 and VH6, and from the constant region MG-25 i.e., 5′-GCACACCGCTGGACAGGGATCCAiAGTTTC-3′, which, containing inosine as shown recognizes murine γ1, γ2A, γ2B, and γ3.
- For amplification of the heavy chain of the antibody derived from D5.1 (which contains the human μ constant region), MG-24VI was used to prime from the variable and μP1 (5′-TTTTCTTTGTTGCCGTTGGGGTGC-3′) was used to prime from the constant region terminus.
- Turning first to the results shown in
FIG. 16 representing the heavy chain of the Mab secreted by K4.1, the sequence shows the presence of the human variable segment VH6, the human diversity region DN1, and the human joining segment JH4 linked to the murine γ1 constant region. Nine base-pair mutations from the published germline sequence were present in the variable region, two of them within CDR2. One mutation was observed in the D segment. Three nongermline nucleotide additions were present in the DH-JH junction. - Referring to
FIG. 17 which shows the light chain of the K4.1 antibody, analysis shows the presence of the human kappa variable region B3 and joining region JK4. Eight nucleotides are missing from B3 at the VK-JK junction and four mutations were found in the variable region. Five nongermline nucleotide additions were present at the VK-JK junction. - Referring now to
FIG. 18 which sets forth the sequence for the heavy chain of the antibody secreted by clone D5.1, this shows the heavy chain is comprised of the human variable fragment VH6, the human diversity region DN1 and the human joining segment JH4 linked to the human μ constant region. There were two base-pair mutations from the germline sequence in the variable region, neither within the CDRs. Two additional mutations were in the D segment and six nongermline nucleotide additions were present at the DH-JH junction. - Finally, referring to
FIG. 19 which presents the light chain of the antibody secreted by D5.1, the human kappa variable region B3 and human kappa joining region JK3 are shown. There are nine base-pair differences from the germline sequences, three falling within CDR1.
Claims (99)
1. A method to produce an immunoglobulin with fully human variable region or an analog thereof, specific for a desired antigen, which method comprises:
administering said antigen or an immunogenic portion thereof to a nonhuman animal under conditions to stimulate an immune response, whereby said animal produces B cells that secrete immunoglobulin specific for said antigen; wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy or light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions; and
recovering said immunoglobulin or analog.
2. (canceled)
3. The method of claim 1 wherein said recovering step comprises immortalizing B cells from said animal, screening the resulting immortalized cells for the secretion of said immunoglobulin, and
1) recovering immunoglobulin secreted by said immortalized B cells, or
2) recovering the genes encoding at least the variable region of said immunoglobulin from the immortalized B cells, and optionally modifying said genes;
expressing said genes or modified forms thereof to produce immunoglobulin or analog; and
recovering said immunoglobulin or analog.
4. The method of claim 1 wherein said recovering step comprises
recovering genes encoding at least the variable region of immunoglobulins from the primary B cells of the animal;
generating a library of said genes expressing the variable regions;
screening the library for a variable region with desired affinity for the antigen;
recovering the genes encoding said variable regions;
expressing said recovered genes to produce an immunoglobulin or analog containing said variable region and recovering said immunoglobulin or analog.
5. A recombinant DNA molecule comprising a nucleotide sequence encoding the immunoglobulin or analog produced by the method of claim 1 .
6. (canceled)
7. A cell or cell line modified to contain the DNA molecule of claim 5 .
8. A method to produce an immunoglobulin with fully human variable region or an analog thereof which method comprises culturing the cells of claim 7 under conditions whereby said encoding nucleotide sequence is expressed to produce said immunoglobulin or analog; and recovering said immunoglobulin or analog.
9. A DNA molecule comprising a nucleotide sequence corresponding to the gene or modified gene prepared by the method of claim 3 .
10. (canceled)
11. A cell or cell line modified to contain the DNA molecule of claim 9 .
12. A method to produce an immunoglobulin with fully human variable regions or an analog thereof which method comprises culturing the cells of claim 11 under conditions whereby said encoding nucleotide sequence is expressed to produce said immunoglobulin or analog; and recovering said immunoglobulin or analog.
13. A DNA molecule which comprises a nucleotide sequence encoding a variable region with desired affinity prepared according to the method of claim 4 .
14. (canceled)
15. A cell or cell line modified to contain the DNA molecule of claim 13 .
16. A method to produce an immunoglobulin with fully human variable region or an analog thereof which method comprises culturing the cells of claim 15 under conditions whereby said encoding nucleotide sequence is expressed to produce said immunoglobulin or analog; and recovering said immunoglobulin or analog.
17. An immortalized B cell which secretes an immunoglobulin to a desired antigen with a fully human variable region prepared according to claim 3 .
18. A method to produce an immunoglobulin or analog which comprises culturing the cells of claim 17 and recovering said immunoglobulin or analog.
19. An immunoglobulin with fully human variable region or analog produced by the method of claim 1 .
20. The immunoglobulin or analog of claim 19 wherein the desired antigen is selected from the group consisting of
the leukocyte markers, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a,b,c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27 and its ligand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and isoforms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1 and TCR;
the histocompatibility antigens, MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
the integrins, VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, and LFA-1;
the adhesion molecules, Mac-1 and p150, 95;
the selectins, L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, and LFA-3;
the interleukins, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-13, IL-14, and IL-15;
interleukin receptors, IL-1R, IL-2R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
chemokines, PF4, RANTES, MIP1α, MCP1, NAP-2, Groα, Groβ, and IL-8;
growth factors, TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
growth factor receptors, TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
interferon receptors, IFNαR, IFNβR, and IFNγR;
Igs and their receptors, IgE, FceRI, and FCeRII;
tumor antigens, her2-neu, mucin, CEA and endosialin;
the allergens, house dust mite antigen, lol p1 (grass) antigens, and urushiol;
the viral proteins, CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
the toxins, pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
the blood factors, complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor;
the enzymes, cholesterol ester transfer protein, membrane bound matrix metalloproteases, and Glutamic acid decarboxylase (GAD); and
the miscellaneous antigens ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV collagen, glycated lipids, γ-interferon, A7, P-glycoprotein and Fas (AFO-1) and oxidized-LDL.
21. A DNA molecule comprising a nucleotide sequence that encodes the immunoglobulin or analog of claim 19 .
22. (canceled)
23. A cell or cell line modified to contain the DNA molecule of claim 21 .
24. A method to produce an immunoglobulin or analog specific for the antigen selected from the group consisting of leukocyte markers, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a,b,c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27 and its ligand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and isoforms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1 and TCR
histocompatibility antigens, MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
integrins, VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, and LFA-1;
adhesion molecules, Mac-1 and p150, 95;
selectins, L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, and LFA-3;
interleukins, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-ll, IL-12, IL-13, IL-14, and IL-15;
interleukin receptors, IL-1R, IL-2R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
chemokines, PF4, RANTES, MIP1α, MCP1, NAP-2, Groα, Groβ, and IL-8;
growth factors, TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
growth factor receptors, TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
integrin receptors, IFNαR, IFNβR, and IFNγR;
Igs and their receptors, IgE, FceRI, and FCeR11;
tumor antigens, her2-neu, mucin, CEA and endosialin;
allergens, house dust mite antigen, lol p1 (grass) antigens, and urushiol;
viral proteins, CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
toxins, pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
blood factors, complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor;
enzymes, cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD); and
miscellaneous antigens, ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV dollagen, glycated lipids, γ-interferon, A7, P-glycoprotein and Fas (AFO-1) and oxidized-LDL
which method comprises culturing the cell or cell line of claim 23 under conditions wherein said nucleotide sequence is expressed to produce said immunoglobulin or analog; and
recovering the immunoglobulin or analog.
25. (canceled)
26. A antibody containing a fully human variable region or analog thereof which is specifically immunoreactive with an antigen selected from the group consisting of human IL-6, human IL-8, human TNFα, human CD4, human L-selectin, human gp39 and tetanus toxin C (TTC).
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. The analog of claim 26 which is a single chain Fv.
35. A recombinant DNA molecule encoding the antibody or analog of claim 26 .
36. A recombinant DNA molecule which comprises an expression system for the production of the antibody or analog of claim 26 which expression system comprises a nucleotide sequence encoding said antibody or analog operably linked to control sequences capable of effecting its expression.
37. A recombinant host cell which is modified to contain the DNA molecule of claim 36 .
38. A method to produce an antibody or analog immunospecific for an antigen selected from the group consisting of human IL-6, human IL-8, human TNFα, human CD4, human L-selectin, human gp39 and tetanus toxin C (TTC), which method comprises culturing the cells of claim 37 under conditions wherein said coding sequence is expressed; and recovering the antibody or analog produced.
39. Use of the antibody or analog of claim 27 , 29 , 31 or 32 for treating an autoimmune disease in a mammal.
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. An isolated human antibody or an antigen-binding fragment thereof that specifically binds a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR,
wherein said antibody or fragment modulates the activity of said leukocyte marker.
47. The antibody or fragment according to claim 46 wherein the leukocyte marker is CD4.
48. The antibody or fragment according to claim 46 herein the leukocyte marker is CD8.
49. The antibody or fragment according to claim 46 wherein the leukocyte marker is CD28.
50. The antibody or fragment according to claim 46 wherein the leukocyte marker is CD40.
51. The antibody or fragment according to claim 46 wherein the leukocyte marker is CD45.
52. The antibody or fragment according to claim 46 wherein the leukocyte marker is TCR.
53. The antibody according to any one of claims 46-52, wherein the antibody is monoclonal.
54. The fragment according to any one of claims 46-52, wherein the fragment comprises an scFv, Fab, Fab′, or F(ab′)2 fragment.
55. The antibody according to any one of claims 46-52, wherein the antibody is detectably labeled.
56. The antibody according to any one of claims 46-52, wherein the leukocyte marker is human.
57. The antibody according to any one of claims 46-52, wherein the antibody decreases activity of the leukocyte marker.
58. The antibody according to any one of claims 46-52, wherein the antibody comprises lambda light chain sequence.
59. The antibody according to any one of claims 46-52, wherein the antibody increases an activity of the leukocyte marker.
60. The antibody according to any one of claims 46-52, further comprising a pharmaceutical formulation.
61. A host cell that expresses the antibody according to any one of claims 46-52.
62. A nucleic acid that encodes the antibody according to any one of claims 46-52.
63. A host cell comprising the nucleic acid of claim 62 .
64. A method of producing an isolated human antibody that specifically binds and modulates the activity of a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR comprising:
(a) administering the leukocyte marker or an immunogenic fragment thereof to a mouse capable of expressing human immunoglobulin;
(b) screening the administered mouse for expression of a human antibody that specifically binds to the leukocyte marker;
(c) selecting a mouse that produces a human antibody that specifically binds to the leukocyte marker;
(d) isolating an antibody from the mouse that produces a human antibody that specifically binds to the leukocyte marker; and
(e) determining whether the antibody modulates an activity of the leukocyte marker thereby producing a human antibody that specifically binds to the leukocyte marker and modulates an activity of the leukocyte marker.
65. A method of producing an isolated human antibody that specifically binds to and modulates the activity of a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR comprising:
(a) administering the leukocyte marker or an immunogenic fragment thereof to a mouse capable of expressing human immunoglobulin;
(b) isolating spleen cells from the mouse that produces a human antibody that specifically binds to the leukocyte marker;
(c) fusing the spleen cells with a myeloma cell to produce a hybridoma; and
(d) screening the hybridoma for expression of a human antibody that specifically binds to and modulates an activity of the leukocyte marker thereby producing a human monoclonal antibody that specifically binds to and modulates an activity of the leukocyte marker.
66. The method according to claim 64 or 65 wherein the leukocyte marker is CD4.
67. The method according to claim 64 or 65 wherein the leukocyte marker is CD8.
68. The method according to claim 64 or 65 wherein the leukocyte marker is CD28.
69. The method according to claim 64 or 65 wherein the leukocyte marker is CD40.
70. The method according to claim 64 or 65 wherein the leukocyte marker is CD45.
71. The method according to claim 64 or 65 wherein the leukocyte marker is TCR.
72. A monoclonal antibody isolated from a hybridoma produced by the method of claim 65 .
73. A method for modulating an activity of a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR comprising contacting a cell that expresses the leukocyte marker with a modulating amount of the antibody of claim 46 .
74. The method according to claim 73 wherein the leukocyte marker is CD4.
75. The method according to claim 73 wherein the leukocyte marker is CD8.
76. The method according to claim 73 wherein the leukocyte marker is CD28.
77. The method according to claim 73 wherein the leukocyte marker is CD40.
78. The method according to claim 73 wherein the leukocyte marker is CD45.
79. The method according to claim 73 wherein the leukocyte marker is TCR.
80. The method of claim 73 , wherein the leukocyte marker is human.
81. The method of claim 73 , wherein the activity is increased.
82. The method of claim 73 , wherein the activity is decreased.
83. A method of increasing an activity of a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR in a subject comprising administering to the subject an amount of a human antibody that increases an activity of the leukocyte marker.
84. A method of decreasing an activity of a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR in a subject comprising administering to the subject an amount of a human antibody that decreases an activity of the leukocyte marker.
85. A method of detecting the presence of a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR in a sample or a cell, comprising contacting a sample having or suspected of having the leukocyte marker, or a cell expressing or suspected of expressing the leukocyte marker, with the antibody of claim 1 , and detecting the presence of the leukocyte marker in the sample or cell.
86. The method according to claim 83 , 84 or 85, wherein the leukocyte marker is CD4.
87. The method according to claim 83 , 84 or 85, wherein the leukocyte marker is CD8.
88. The method according to claim 83 , 84 or 85, wherein the leukocyte marker is CD28.
89. The method according to claim 83 , 84 or 85, wherein the leukocyte marker is CD40.
90. The method according to claim 83 , 84 or 85, wherein the leukocyte marker is CD45.
91. The method according to claim 83 , 84 or 85, wherein the leukocyte marker is TCR.
92. The method of claim 85 , wherein the cell is in a subject.
93. A method of detecting the presence of a disorder associated with increased or decreased expression of a a leukocyte marker selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a, b, c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27, CD28, CD29, CD30, CD40, CD44, CD45 and isoforms, Cdw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1, and TCR in a human, comprising contacting a sample having or suspected of having the leukocyte marker or a cell expressing or suspected of expressing the leukocyte marker, wherein the sample or cell is from or present in the human, with the human antibody of claim 46 and detecting the presence of increased or decreased expression of the leukocte marker in the sample or cell relative to a control thereby detecting the presence of a disorder associated with increased or decreased expression of the leukocyte marker in the human.
94. The method according to claim 93 , wherein the leukocyte marker is CD4.
95. The method according to claim 93 , wherein the leukocyte marker is CD8.
96. The method according to claim 93 , wherein the leukocyte marker is CD28.
97. The method according to claim 93 , wherein the leukocyte marker is CD40.
98. The method according to claim 93 , wherein the leukocyte marker is CD45.
99. The method according to claim 93 , wherein the leukocyte marker is TCR.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/656,623 US20060040363A1 (en) | 1990-01-12 | 2003-09-04 | Human antibodies derived from immunized xenomice |
US10/978,290 US20050241006A1 (en) | 1995-04-27 | 2004-10-29 | Human antibodies derived from immunized xenomice |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46600890A | 1990-01-12 | 1990-01-12 | |
US61051590A | 1990-11-08 | 1990-11-08 | |
US91929792A | 1992-07-24 | 1992-07-24 | |
US08/031,801 US6673986B1 (en) | 1990-01-12 | 1993-03-15 | Generation of xenogeneic antibodies |
US11284893A | 1993-08-27 | 1993-08-27 | |
US23414594A | 1994-04-28 | 1994-04-28 | |
US43093895A | 1995-04-27 | 1995-04-27 | |
US08/923,138 US6657103B1 (en) | 1990-01-12 | 1997-09-04 | Human antibodies derived from immunized xenomice |
US10/656,623 US20060040363A1 (en) | 1990-01-12 | 2003-09-04 | Human antibodies derived from immunized xenomice |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/923,138 Continuation US6657103B1 (en) | 1990-01-12 | 1997-09-04 | Human antibodies derived from immunized xenomice |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/978,290 Continuation US20050241006A1 (en) | 1995-04-27 | 2004-10-29 | Human antibodies derived from immunized xenomice |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060040363A1 true US20060040363A1 (en) | 2006-02-23 |
Family
ID=29554595
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/923,138 Expired - Fee Related US6657103B1 (en) | 1990-01-12 | 1997-09-04 | Human antibodies derived from immunized xenomice |
US10/656,623 Abandoned US20060040363A1 (en) | 1990-01-12 | 2003-09-04 | Human antibodies derived from immunized xenomice |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/923,138 Expired - Fee Related US6657103B1 (en) | 1990-01-12 | 1997-09-04 | Human antibodies derived from immunized xenomice |
Country Status (1)
Country | Link |
---|---|
US (2) | US6657103B1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070269868A1 (en) * | 2006-05-19 | 2007-11-22 | Carvalho Jensen Anne E | Culture method for obtaining a clonal population of antigen-specific B cells |
US20090291089A1 (en) * | 2007-05-21 | 2009-11-26 | Smith Jeffrey T L | Antagonists of IL-6 to prevent or treat Thrombosis |
US20090291085A1 (en) * | 2007-02-16 | 2009-11-26 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
WO2010054403A1 (en) | 2008-11-10 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
WO2010056898A2 (en) * | 2008-11-12 | 2010-05-20 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory b cells |
US20100150829A1 (en) * | 2008-11-25 | 2010-06-17 | Leon Garcia-Martinez | Antibodies to IL-6 and use thereof |
US20100290993A1 (en) * | 2007-05-21 | 2010-11-18 | Leon Garcia-Martinez | Antibodies to IL-6 and use thereof |
US20110027291A1 (en) * | 2008-08-15 | 2011-02-03 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
WO2011085343A1 (en) | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
US20110217303A1 (en) * | 2007-05-21 | 2011-09-08 | Smith Jeffrey T L | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US20110236378A1 (en) * | 2008-09-30 | 2011-09-29 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
WO2011137395A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anti-c5a antibodies and methods for using the antibodies |
WO2012020096A1 (en) | 2010-08-13 | 2012-02-16 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
EP2463305A1 (en) | 2006-01-12 | 2012-06-13 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
WO2012106634A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
US20140017238A1 (en) | 2001-02-16 | 2014-01-16 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US8992908B2 (en) | 2010-11-23 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
US9085615B2 (en) | 2008-11-25 | 2015-07-21 | Alderbio Holdings Llc | Antibodies to IL-6 to inhibit or treat inflammation |
US9187560B2 (en) | 2008-11-25 | 2015-11-17 | Alderbio Holdings Llc | Antagonists of IL-6 to treat cachexia, weakness, fatigue, and/or fever |
WO2015175874A2 (en) | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9241990B2 (en) | 2007-05-21 | 2016-01-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRIP |
US9265825B2 (en) | 2008-11-25 | 2016-02-23 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9468676B2 (en) | 2009-11-24 | 2016-10-18 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9688761B2 (en) | 2013-12-27 | 2017-06-27 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US9725509B2 (en) | 2007-05-21 | 2017-08-08 | Alderbio Holdings Llc | Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
US9834603B2 (en) | 2007-05-21 | 2017-12-05 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
US10344299B2 (en) | 2000-10-31 | 2019-07-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for modifying cells |
EP3524626A1 (en) | 2007-03-22 | 2019-08-14 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050241006A1 (en) * | 1995-04-27 | 2005-10-27 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US20050287630A1 (en) * | 1995-04-27 | 2005-12-29 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
AU2001283062A1 (en) * | 2000-08-02 | 2002-02-13 | The Johns Hopkins University | Endothelial cell expression patterns |
MX349009B (en) | 2001-01-05 | 2017-07-06 | Pfizer | Antibodies to insulin-like growth factor i receptor. |
US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
AU2003225009A1 (en) * | 2002-04-22 | 2003-11-03 | Dyax Corporation | Antibodies specific for mucin polypeptide |
EP1575491A4 (en) * | 2002-05-20 | 2006-09-27 | Abgenix Inc | Treatment of renal carcinoma using antibodies against the egfr |
ATE458196T1 (en) * | 2002-06-26 | 2010-03-15 | Univ Louisville Res Found | METHOD FOR DETECTING APOPTOSIS |
WO2005011619A2 (en) * | 2003-01-31 | 2005-02-10 | Five Prime Therapeutics, Inc. | Lung-expressed polypeptides |
NZ582210A (en) * | 2003-02-13 | 2011-04-29 | Pfizer Prod Inc | Uses of anti-insulin-like growth factor I receptor antibodies |
US20040241808A1 (en) * | 2003-04-14 | 2004-12-02 | Renata Pasqualini | Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations |
EP1656391B1 (en) * | 2003-08-13 | 2010-10-13 | Pfizer Products Inc. | Modified human igf-1r antibodies |
US8114969B2 (en) * | 2003-10-01 | 2012-02-14 | Isis Innovation, Ltd. | Immunotoxin derived from a recombinant human autoantibody and method of using thereof |
CA2545756A1 (en) * | 2003-11-07 | 2005-05-26 | Curagen Corporation | Antibodies against secretoryleukocyte protease inhibitor |
AU2005250370B2 (en) | 2004-05-28 | 2010-04-01 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
KR20080019733A (en) * | 2004-07-16 | 2008-03-04 | 화이자 프로덕츠 인코포레이티드 | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
HUE025945T2 (en) | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-cd19 antibodies and uses in oncology |
EP2444099A1 (en) | 2005-03-31 | 2012-04-25 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP2010569A4 (en) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | Human antibodies specific for gastrin materials and methods |
AU2007240614B2 (en) | 2006-04-20 | 2013-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated | Methods and compositions based on Shiga toxin type 1 protein |
EP3124045A3 (en) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Treatment of il-1 beta related diseases |
KR102096731B1 (en) * | 2007-06-01 | 2020-04-02 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
JP5536666B2 (en) | 2007-12-20 | 2014-07-02 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | Methods for the treatment of gout |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2011004192A1 (en) | 2009-07-08 | 2011-01-13 | Genome Research Limited | Animal models and therapeutic molecules |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
JP5885664B2 (en) | 2009-09-25 | 2016-03-15 | ゾーマ テクノロジー リミテッド | Screening method |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
PT2501817E (en) | 2010-02-08 | 2015-11-04 | Regeneron Pharma | Common light chain mouse |
US8609092B2 (en) | 2010-02-08 | 2013-12-17 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
RU2612903C2 (en) | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Mouse producing binding proteins containing vl-domains |
WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
KR20240013851A (en) | 2010-09-29 | 2024-01-30 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
NZ776770A (en) | 2011-02-25 | 2023-03-31 | Regeneron Pharma | Adam6 mice |
EP3011974B1 (en) | 2011-06-02 | 2018-08-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
EP3954704A1 (en) | 2011-06-03 | 2022-02-16 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
ES2758051T3 (en) | 2011-08-05 | 2020-05-04 | Regeneron Pharma | Humanized Universal Light Chain Mice |
CN103945689B (en) | 2011-09-19 | 2016-10-19 | 科马布有限公司 | The multifarious manipulation of immunoglobulin gene and multispecific antibody therapeutic agent |
SI2627773T1 (en) * | 2011-10-17 | 2017-12-29 | Regeneron Pharmaceuticals, Inc., | Restricted immunoglobulin heavy chain mice |
WO2013057628A1 (en) | 2011-10-21 | 2013-04-25 | Pfizer Inc. | Addition of iron to improve cell culture |
WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
PL2793567T3 (en) | 2011-12-20 | 2019-09-30 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
EP3912464A1 (en) * | 2012-06-12 | 2021-11-24 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
SG11201501286PA (en) | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
TW201414837A (en) | 2012-10-01 | 2014-04-16 | Univ Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
SI2840892T1 (en) | 2013-02-20 | 2018-08-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
RU2679657C2 (en) | 2013-08-01 | 2019-02-12 | Эдженсис, Инк. | Antibody drug conjugates that bind to cd37 proteins |
CN105683365A (en) | 2013-10-01 | 2016-06-15 | 科马布有限公司 | Animal models and therapeutic molecules |
US10544395B2 (en) | 2014-03-19 | 2020-01-28 | Pfizer Inc. | Method of cell culture |
SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
CA2941514A1 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
WO2016141111A1 (en) | 2015-03-03 | 2016-09-09 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
WO2016145099A1 (en) | 2015-03-09 | 2016-09-15 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
CN108136001B (en) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | Treatment of cancer using TGF-beta inhibitors and PD-1 inhibitors |
CA3020885A1 (en) | 2015-05-05 | 2016-11-10 | Mohammad Tariq MALIK | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
US10253101B2 (en) | 2015-08-06 | 2019-04-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
WO2017051347A2 (en) | 2015-09-23 | 2017-03-30 | Pfizer Inc. | Cells and method of cell culture |
RU2709378C1 (en) | 2016-04-05 | 2019-12-17 | Пфайзер Инк. | Cell culture technique |
CN109803680B (en) | 2016-08-01 | 2024-05-17 | 佐马美国有限公司 | Parathyroid hormone receptor 1 (PTH 1R) antibodies and uses thereof |
WO2018064255A2 (en) | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
CA3056182A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
US20200255785A1 (en) | 2017-09-15 | 2020-08-13 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
BR112020013094A2 (en) * | 2017-12-29 | 2021-03-30 | Zhuhai Trinomab Biotechnology Co., Ltd. | TOTALLY HUMAN NATURAL NEUTRALIZING MONOCLONAL ANTIBODY AGAINST TETANIC TOXIN AND ITS APPLICATIONS |
CN111902160A (en) | 2018-03-16 | 2020-11-06 | 百时美施贵宝公司 | Metabolic enzyme activity and disulfide bond reduction during protein production |
JP7475687B2 (en) | 2018-09-21 | 2024-04-30 | 国立大学法人 東京医科歯科大学 | Human monoclonal antibody that specifically binds to human HMGB1, and pharmaceutical composition containing the same for treating or preventing Alzheimer's disease |
US20220073942A1 (en) | 2018-12-06 | 2022-03-10 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
KR20210153092A (en) | 2019-04-15 | 2021-12-16 | 퀴셀 세라퓨틱스 엘엘씨 | Fusion protein composition comprising masked type I interferons (IFNA and IFNB) and antibodies to tumor antigens, for use in the treatment of cancer |
JP2022538674A (en) | 2019-07-01 | 2022-09-05 | トニックス ファーマ リミテッド | ANTI-CD154 ANTIBODY AND USES THEREOF |
US20240058466A1 (en) | 2019-10-04 | 2024-02-22 | TAE Life Sciences | Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof |
EP4260872A1 (en) | 2020-12-09 | 2023-10-18 | National University Corporation Tokyo Medical and Dental University | Agent for preventing or treating frontotemporal lobar degeneration |
CA3207098A1 (en) | 2021-01-06 | 2022-07-14 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
CA3221878A1 (en) | 2021-06-18 | 2022-12-22 | David Stover | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof |
WO2023079058A1 (en) | 2021-11-05 | 2023-05-11 | Yokogawa Insilico Biotechnology Gmbh | Cell culture with reduced production of lactate |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816397A (en) * | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
US4959313A (en) * | 1987-06-22 | 1990-09-25 | The Jackson Laboratory | Cellular enhancer for expressing genes in undifferentiated stem cells |
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5545807A (en) * | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5559012A (en) * | 1993-07-23 | 1996-09-24 | Immunotech | Therapeutic, IL-6 antibody kits, and process for their preparation |
US5569824A (en) * | 1991-01-04 | 1996-10-29 | Baylor College Of Medicine | Transgenic mice containing a disrupted p53 gene |
US5569825A (en) * | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5591669A (en) * | 1988-12-05 | 1997-01-07 | Genpharm International, Inc. | Transgenic mice depleted in a mature lymphocytic cell-type |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2637613B1 (en) | 1987-06-19 | 1991-09-27 | Transgene Sa | PROCESS FOR THE PREPARATION OF STABLE CELL LINES FOR THE PRODUCTION OF DETERMINED PROTEINS FROM TRANSGENIC ANIMALS; TUMOR CELL LINES AND PROTEINS OBTAINED |
DE3853201T2 (en) | 1987-12-23 | 1995-09-14 | Univ Leland Stanford Junior | Chimeric immunocompromising mammals and their use. |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
JP3008208B2 (en) | 1990-06-01 | 2000-02-14 | 武田薬品工業株式会社 | Novel hybridoma, its production method and production method of bioactive substance |
GB9119338D0 (en) | 1991-09-10 | 1991-10-23 | Inst Of Animal Physiology And | Control of gene expression |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ATE390933T1 (en) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
-
1997
- 1997-09-04 US US08/923,138 patent/US6657103B1/en not_active Expired - Fee Related
-
2003
- 2003-09-04 US US10/656,623 patent/US20060040363A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816397A (en) * | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
US4959313A (en) * | 1987-06-22 | 1990-09-25 | The Jackson Laboratory | Cellular enhancer for expressing genes in undifferentiated stem cells |
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5545807A (en) * | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
US5591669A (en) * | 1988-12-05 | 1997-01-07 | Genpharm International, Inc. | Transgenic mice depleted in a mature lymphocytic cell-type |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5569825A (en) * | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5569824A (en) * | 1991-01-04 | 1996-10-29 | Baylor College Of Medicine | Transgenic mice containing a disrupted p53 gene |
US5559012A (en) * | 1993-07-23 | 1996-09-24 | Immunotech | Therapeutic, IL-6 antibody kits, and process for their preparation |
Cited By (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10344299B2 (en) | 2000-10-31 | 2019-07-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for modifying cells |
US9708635B2 (en) | 2000-10-31 | 2017-07-18 | Regeneron Pharmaceuticals, Inc. | Methods of making a nucleic acid encoding a human variable region |
US9376699B2 (en) | 2000-10-31 | 2016-06-28 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
US10227625B2 (en) | 2000-10-31 | 2019-03-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US10584364B2 (en) | 2000-12-07 | 2020-03-10 | Rgeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US10378040B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US10526630B2 (en) | 2001-02-16 | 2020-01-07 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice that produce hybrid antibodies |
US10378038B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US20140017238A1 (en) | 2001-02-16 | 2014-01-16 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
US10378037B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Methods of making a nucleic acid encoding a human variable region |
US10378039B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus |
US9371553B2 (en) | 2001-02-16 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice that produce hybrid antibodies |
US9353394B2 (en) | 2001-02-16 | 2016-05-31 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
US9528136B2 (en) | 2001-02-16 | 2016-12-27 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US9388446B2 (en) | 2001-02-16 | 2016-07-12 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
US10640800B2 (en) | 2001-02-16 | 2020-05-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
EP2463305A1 (en) | 2006-01-12 | 2012-06-13 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
WO2008045140A1 (en) * | 2006-05-19 | 2008-04-17 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
US20070269868A1 (en) * | 2006-05-19 | 2007-11-22 | Carvalho Jensen Anne E | Culture method for obtaining a clonal population of antigen-specific B cells |
US20110123523A1 (en) * | 2007-02-16 | 2011-05-26 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
US8961966B2 (en) | 2007-02-16 | 2015-02-24 | Merrimack Pharmaceuticals, Inc. | Antibodies against ERBB3 and uses thereof |
US20090291085A1 (en) * | 2007-02-16 | 2009-11-26 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
US20100266584A1 (en) * | 2007-02-16 | 2010-10-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
US7846440B2 (en) | 2007-02-16 | 2010-12-07 | Merrimack Pharmaceuticals, Inc. | Antibodies against ErbB3 and uses thereof |
US9487588B2 (en) | 2007-02-16 | 2016-11-08 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of ERBB3 and uses thereof |
US8691225B2 (en) | 2007-02-16 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of ErbB3 and uses thereof |
EP3524626A1 (en) | 2007-03-22 | 2019-08-14 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
US10040851B2 (en) | 2007-05-21 | 2018-08-07 | Alderbio Holdings Llc | Antagonists to IL-6 to raise albumin and/or lower CRP |
US9834603B2 (en) | 2007-05-21 | 2017-12-05 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9926370B2 (en) | 2007-05-21 | 2018-03-27 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9884912B2 (en) | 2007-05-21 | 2018-02-06 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US20110217303A1 (en) * | 2007-05-21 | 2011-09-08 | Smith Jeffrey T L | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8999330B2 (en) | 2007-05-21 | 2015-04-07 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9546213B2 (en) | 2007-05-21 | 2017-01-17 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US20090291089A1 (en) * | 2007-05-21 | 2009-11-26 | Smith Jeffrey T L | Antagonists of IL-6 to prevent or treat Thrombosis |
US10787507B2 (en) | 2007-05-21 | 2020-09-29 | Vitaeris Inc. | Antagonists of IL-6 to prevent or treat thrombosis |
US10913794B2 (en) | 2007-05-21 | 2021-02-09 | Vitaeris Inc. | Antibodies to IL-6 and use thereof |
US10160804B2 (en) | 2007-05-21 | 2018-12-25 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US10344086B2 (en) | 2007-05-21 | 2019-07-09 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US10800841B2 (en) | 2007-05-21 | 2020-10-13 | Vitaeris, Inc. | Methods of treating autoimmunity using specific anti-IL-6 antibodies |
US9725509B2 (en) | 2007-05-21 | 2017-08-08 | Alderbio Holdings Llc | Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9241990B2 (en) | 2007-05-21 | 2016-01-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRIP |
US20100290993A1 (en) * | 2007-05-21 | 2010-11-18 | Leon Garcia-Martinez | Antibodies to IL-6 and use thereof |
US10759853B2 (en) | 2007-05-21 | 2020-09-01 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9758579B2 (en) | 2007-05-21 | 2017-09-12 | Alder Bioholdings, Llc | Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity |
US10233239B2 (en) | 2007-05-21 | 2019-03-19 | Alderbio Holdings Llc | Isolated host cells expressing anti-IL-6 antibodies |
US11827700B2 (en) | 2007-05-21 | 2023-11-28 | Vitaeris Inc. | Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies |
US9771421B2 (en) | 2007-05-21 | 2017-09-26 | Alderbio Holdings Llc | Treating anemia in chronic IL-6 associated diseases using anti-IL-6 antibodies |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
US20110027291A1 (en) * | 2008-08-15 | 2011-02-03 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
US20110159513A1 (en) * | 2008-08-15 | 2011-06-30 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
US20110236378A1 (en) * | 2008-09-30 | 2011-09-29 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10561123B2 (en) | 2008-09-30 | 2020-02-18 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10492476B2 (en) | 2008-09-30 | 2019-12-03 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10555506B2 (en) | 2008-09-30 | 2020-02-11 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10638736B2 (en) | 2008-09-30 | 2020-05-05 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10575504B2 (en) | 2008-09-30 | 2020-03-03 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
EP3121197A1 (en) | 2008-11-10 | 2017-01-25 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP2894165A1 (en) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP3101031A1 (en) | 2008-11-10 | 2016-12-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP2894166A1 (en) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP3974448A1 (en) | 2008-11-10 | 2022-03-30 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complementassociated disorders |
WO2010054403A1 (en) | 2008-11-10 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
US8840890B2 (en) | 2008-11-12 | 2014-09-23 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory B cells |
US20110223615A1 (en) * | 2008-11-12 | 2011-09-15 | University Of Maryland, Baltimore | Rapid Expression Cloning of Human Monoclonal Antibodies from Memory B Cells |
WO2010056898A3 (en) * | 2008-11-12 | 2010-10-07 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory b cells |
WO2010056898A2 (en) * | 2008-11-12 | 2010-05-20 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory b cells |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9187560B2 (en) | 2008-11-25 | 2015-11-17 | Alderbio Holdings Llc | Antagonists of IL-6 to treat cachexia, weakness, fatigue, and/or fever |
US20100150829A1 (en) * | 2008-11-25 | 2010-06-17 | Leon Garcia-Martinez | Antibodies to IL-6 and use thereof |
US9085615B2 (en) | 2008-11-25 | 2015-07-21 | Alderbio Holdings Llc | Antibodies to IL-6 to inhibit or treat inflammation |
US9265825B2 (en) | 2008-11-25 | 2016-02-23 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9879074B2 (en) | 2008-11-25 | 2018-01-30 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US10640560B2 (en) | 2008-11-25 | 2020-05-05 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and /or fever |
US10858424B2 (en) | 2008-11-25 | 2020-12-08 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US10787511B2 (en) | 2008-11-25 | 2020-09-29 | Vitaeris Inc. | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9765138B2 (en) | 2008-11-25 | 2017-09-19 | Alderbio Holdings Llc | Isolated anti-IL-6 antibodies |
US9994635B2 (en) | 2008-11-25 | 2018-06-12 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US10117955B2 (en) | 2008-11-25 | 2018-11-06 | Alderbio Holdings Llc | Methods of aiding in the diagnosis of diseases using anti-IL-6 antibodies |
US10053506B2 (en) | 2008-11-25 | 2018-08-21 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US10391169B2 (en) | 2009-07-28 | 2019-08-27 | Alderbio Holdings Llc | Method of treating allergic asthma with antibodies to IL-6 |
US9468676B2 (en) | 2009-11-24 | 2016-10-18 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9717793B2 (en) | 2009-11-24 | 2017-08-01 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by administering an anti-IL-6 antibody |
US9821057B2 (en) | 2009-11-24 | 2017-11-21 | Alderbio Holdings Llc | Anti-IL-6 antibody for use in the treatment of cachexia |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
US10471143B2 (en) | 2009-11-24 | 2019-11-12 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9724410B2 (en) | 2009-11-24 | 2017-08-08 | Alderbio Holdings Llc | Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity |
WO2011085343A1 (en) | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
US9518130B2 (en) | 2010-03-11 | 2016-12-13 | Merrimack Pharmaceuticals, Inc. | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US10662255B2 (en) | 2010-03-31 | 2020-05-26 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10604587B2 (en) | 2010-03-31 | 2020-03-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11352444B2 (en) | 2010-03-31 | 2022-06-07 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11242409B2 (en) | 2010-03-31 | 2022-02-08 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11220555B2 (en) | 2010-03-31 | 2022-01-11 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11104743B2 (en) | 2010-03-31 | 2021-08-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10494445B2 (en) | 2010-03-31 | 2019-12-03 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11104744B2 (en) | 2010-03-31 | 2021-08-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10526420B2 (en) | 2010-03-31 | 2020-01-07 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10836832B2 (en) | 2010-03-31 | 2020-11-17 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10829564B2 (en) | 2010-03-31 | 2020-11-10 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10626188B2 (en) | 2010-03-31 | 2020-04-21 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10618977B2 (en) | 2010-03-31 | 2020-04-14 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
WO2011137395A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anti-c5a antibodies and methods for using the antibodies |
US9309310B2 (en) | 2010-04-30 | 2016-04-12 | Alexion Pharmaceuticals, Inc. | Nucleic acids encoding anti-C5a antibodies |
US11407821B2 (en) | 2010-04-30 | 2022-08-09 | Alexion Pharmaceuticals, Inc. | Anti-C5A antibodies |
EP2824111A2 (en) | 2010-04-30 | 2015-01-14 | Alexion Pharmaceuticals, Inc. | Anti-C5A Antibodies and Methods for Using the Antibodies |
US10450370B2 (en) | 2010-04-30 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9469690B2 (en) | 2010-04-30 | 2016-10-18 | Alexion Pharmaceuticals, Inc. | Methods of treating complement-associated disorders with anti-C5a antibodies |
US9963503B2 (en) | 2010-04-30 | 2018-05-08 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5a antibodies |
US9371378B1 (en) | 2010-04-30 | 2016-06-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9221901B2 (en) | 2010-04-30 | 2015-12-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement-associated disorders with anti-C5a antibodies |
US9434784B1 (en) | 2010-04-30 | 2016-09-06 | Alexion Pharmaceuticals, Inc. | Nucleic acids encodng anti-C5A antibodies |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
WO2012020096A1 (en) | 2010-08-13 | 2012-02-16 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
US9957321B2 (en) | 2010-11-23 | 2018-05-01 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
US8992908B2 (en) | 2010-11-23 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
WO2012106634A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
US9688761B2 (en) | 2013-12-27 | 2017-06-27 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies |
US10273304B2 (en) | 2013-12-27 | 2019-04-30 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies |
EP3888690A2 (en) | 2014-05-16 | 2021-10-06 | MedImmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
WO2015175874A2 (en) | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US6657103B1 (en) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6075181A (en) | Human antibodies derived from immunized xenomice | |
US20060040363A1 (en) | Human antibodies derived from immunized xenomice | |
CA2219361C (en) | Human antibodies derived from immunized xenomice | |
AU2466895A (en) | Human antibodies derived from immunized xenomice | |
US20050054055A1 (en) | Human antibodies derived from immunized xenomice | |
US6150584A (en) | Human antibodies derived from immunized xenomice | |
KR19990008197A (en) | Human Antibodies from Immunized Genomous | |
US20050287630A1 (en) | Human antibodies derived from immunized xenomice | |
US20050241006A1 (en) | Human antibodies derived from immunized xenomice | |
AU2006200868B2 (en) | Human Antibodies Derived From Immunized Xenomice | |
AU5336100A (en) | Human antibodies derived from immunized xenomice | |
AU2008202860B2 (en) | Human Antibodies Derived From Immunized Xenomice | |
AU2003227322B2 (en) | Human Antibodies Derived From Immunized Xenomice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |